View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 24, 2016	Oct. 17, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	CHARLES RIVER LABORATORIES INTERNATIONAL INC
Entity Central Index Key	0001100682
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 24, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		47,328,587

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Income Statement [Abstract]
Service revenue	$ 292,849	$ 222,506	$ 806,397	$ 633,666
Product revenue	132,871	126,959	408,246	375,786
Total revenue	425,720	349,465	1,214,643	1,009,452
Costs and expenses:
Cost of services provided (excluding amortization of intangible assets)	200,118	145,165	543,588	425,614
Cost of products sold (excluding amortization of intangible assets)	69,332	66,225	204,270	193,320
Selling, general and administrative	85,650	76,225	269,067	218,953
Amortization of intangible assets	11,825	6,410	29,390	17,385
Operating income	58,795	55,440	168,328	154,180
Other income (expense):
Interest income	523	177	1,008	758
Interest expense	(7,079)	(3,851)	(20,199)	(11,251)
Other income (expense), net	1,017	1,390	10,059	1,749
Income from continuing operations, before income taxes	53,256	53,156	159,196	145,436
Provision for income taxes	15,565	15,255	48,385	26,662
Income from continuing operations, net of income taxes	37,691	37,901	110,811	118,774
Income (loss) from discontinued operations, net of income taxes	342	(34)	328	(48)
Net income	38,033	37,867	111,139	118,726
Less: Net income attributable to noncontrolling interests	298	488	1,054	1,297
Net income attributable to common shareholders	$ 37,735	$ 37,379	$ 110,085	$ 117,429
Basic:
Continuing operations attributable to common shareholders (in dollars per share)	$ 0.79	$ 0.81	$ 2.34	$ 2.52
Discontinued operations (in dollars per share)	0.01	0.00	0.00	0.00
Net income attributable to common shareholders (in dollars per share)	0.80	0.81	2.34	2.52
Diluted:
Continuing operations attributable to common shareholders (in dollars per share)	0.78	0.79	2.29	2.47
Discontinued operations (in dollars per share)	0.01	0.00	0.01	0.00
Net income attributable to common shareholders (in dollars per share)	$ 0.79	$ 0.79	$ 2.30	$ 2.47

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 38,033	$ 37,867	$ 111,139	$ 118,726
Other comprehensive income (loss):
Foreign currency translation adjustment and other	(16,888)	(31,843)	(32,798)	(46,559)
Cumulative translation adjustment related to intercompany loan forgiveness	0	0	0	(2,341)
Amortization of net loss and prior service benefit included in net periodic cost for pension and other post-retirement benefit plans	1,176	695	1,961	2,185
Comprehensive income, before income taxes	22,321	6,719	80,302	72,011
Income tax expense related to items of other comprehensive income	140	220	424	700
Comprehensive income, net of income taxes	22,181	6,499	79,878	71,311
Less: Comprehensive income (loss) related to noncontrolling interests, net of income taxes	0	(443)	(9)	435
Comprehensive income attributable to common shareholders, net of income taxes	$ 22,181	$ 6,942	$ 79,887	$ 70,876

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 24, 2016	Dec. 26, 2015
Current assets:
Cash and cash equivalents	$ 105,722	$ 117,947
Trade receivables, net	359,734	270,068
Inventories	99,374	93,735
Prepaid assets	36,827	30,198
Other current assets	52,921	47,286
Total current assets	654,578	559,234
Property, plant and equipment, net	767,177	677,959
Goodwill	763,576	438,829
Client relationships and Other intangible assets, net	396,452	280,804
Deferred tax assets	22,078	40,028
Other assets	86,329	71,643
Total assets	2,690,190	2,068,497
Current liabilities:
Current portion of long-term debt and capital leases	25,970	17,033
Accounts payable	65,809	36,675
Accrued compensation	93,558	72,832
Deferred revenue	119,298	81,343
Accrued liabilities	80,524	89,494
Other current liabilities	25,131	12,544
Current liabilities of discontinued operations	1,757	1,840
Total current liabilities	412,047	311,761
Long-term debt, net and capital leases	1,233,189	845,997
Deferred tax liabilities	54,068	48,223
Other long-term liabilities	96,771	89,062
Long-term liabilities of discontinued operations	6,213	7,890
Total liabilities	1,802,288	1,302,933
Commitments and contingencies
Redeemable noncontrolling interest	15,040	28,008
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.01 par value; 120,000 shares authorized; 86,262 shares issued and 47,324 shares outstanding as of September 24, 2016 and 85,464 shares issued and 46,698 shares outstanding as of December 26, 2015	863	855
Additional paid-in capital	2,465,193	2,397,960
Retained earnings	120,623	10,538
Treasury stock, at cost 38,938 shares and 38,766 shares as of September 24, 2016 and December 26, 2015, respectively	(1,552,964)	(1,540,738)
Accumulated other comprehensive loss	(165,746)	(135,548)
Total equity attributable to common shareholders	867,969	733,067
Noncontrolling interests	4,893	4,489
Total equity	872,862	737,556
Total liabilities, redeemable noncontrolling interest and equity	2,690,190	2,068,497
Client relationships, net
Current assets:
Client relationships and Other intangible assets, net	318,751	213,374
Other intangible assets, net
Current assets:
Client relationships and Other intangible assets, net	$ 77,701	$ 67,430

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Sep. 24, 2016	Dec. 26, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	86,262,000	85,464,000
Common stock, shares outstanding (in shares)	47,324,000	46,698,000
Treasury stock (in shares)	38,938,000	38,766,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015
Cash flows relating to operating activities
Net income	$ 111,139	$ 118,726
Less: Income (loss) from discontinued operations, net of income taxes	328	(48)
Income from continuing operations, net of income taxes	110,811	118,774
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Depreciation and amortization	91,116	69,330
Amortization of debt issuance costs and discounts	2,325	1,970
Stock-based compensation	32,647	30,349
Deferred income taxes	(270)	(4,235)
Gain on venture capital investments	(8,518)	(3,604)
Gain on bargain purchase	16	(9,933)
Other, net	4,030	1,101
Changes in assets and liabilities:
Trade receivables, net	(43,260)	(36,430)
Inventories	(4,352)	(470)
Other assets	(5,702)	8,308
Accounts payable	17,184	(894)
Accrued compensation	8,163	2,238
Deferred revenue	2,169	1,255
Accrued liabilities	(15,182)	22,189
Taxes payable and prepaid taxes	(5,671)	(1,906)
Other liabilities	617	(12,147)
Net cash provided by operating activities	186,123	185,895
Cash flows relating to investing activities
Acquisition of businesses and assets, net of cash acquired	(597,607)	(211,974)
Capital expenditures	(29,609)	(35,008)
Purchases of investments	(20,278)	(26,315)
Proceeds from sale of investments and distributions from venture capital investments	28,274	24,562
Other, net	3,790	(244)
Net cash used in investing activities	(615,430)	(248,979)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility	926,781	453,778
Proceeds from exercises of stock options	21,643	36,587
Payments on long-term debt, revolving credit facility and capital lease obligations	(526,983)	(391,048)
Purchase of treasury stock	(12,226)	(117,431)
Other, net	4,976	6,674
Net cash provided by (used in) financing activities	414,191	(11,440)
Discontinued operations
Net cash used in operating activities from discontinued operations	(1,434)	(1,265)
Effect of exchange rate changes on cash and cash equivalents	4,325	(10,202)
Net change in cash and cash equivalents	(12,225)	(85,991)
Cash and cash equivalents, beginning of period	117,947	160,023
Cash and cash equivalents, end of period	$ 105,722	$ 74,032

Basis of Presentation

9 Months Ended

Sep. 24, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission. The year-end condensed consolidated balance sheet data was derived from the Company’s audited financial statements, but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year 2015. The condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations.

The Company’s fiscal year is typically based on a 52-week year, with each quarter composed of 13 weeks. A 53-week year will occur during the fiscal year 2016, with an additional week included in the fourth quarter.

Segment Reporting

The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

During the three months ended June 25, 2016, the Company acquired WRH, Inc. (WIL Research), a provider of safety assessment and contract development and manufacturing (CDMO) services. WIL Research’s safety assessment business is reported in the Company’s DSA reportable segment and its CDMO business created a new operating segment, Contract Manufacturing, that is reported as part of the Company’s Manufacturing reportable segment. In addition, changes in the Company’s market strategy for certain services and resulting information provided to the Chief Operating Decision Maker, totaling $1.9 million of revenue and $0.2 million of operating income for the nine months ended September 26, 2015, were reclassified from the Company’s RMS reportable segment to its Manufacturing reportable segment. The Company reported segment results on this basis for all periods presented.

The revised reportable segments are as follows:



Research Models and Services	Discovery and Safety Assessment	Manufacturing Support
Research Models	Discovery Services	Microbial Solutions
Research Model Services	Safety Assessment	Avian
		Biologics
		Contract Manufacturing

Use of Estimates

The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, redeemable noncontrolling interest, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.

Consolidation

The Company’s condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation.

Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies,” in the Company’s Annual Report on Form 10-K for the fiscal year 2015.

Newly Issued Accounting Pronouncements

In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-15, “Classification of Certain Cash Receipts and Cash Payments.” The standard addresses the classification of certain transactions within the statement of cash flows, including cash payments for debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, and distributions received from equity method investments. The ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting.” The standard reduces complexity in several aspects of the accounting for employee share-based compensation, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases.” The standard established the principles that lessees and lessors will apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. The ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the full impact this standard will have on its consolidated financial statements and related disclosures, but expects to recognize substantially all of its leases on the balance sheet by recording a right-to-use asset and a corresponding lease liability.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory,” that simplifies the subsequent measurement of inventories by replacing the current lower of cost or market test with a lower of cost or net realizable value test. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” The standard, including subsequently issued amendments, will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. The standard will require an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will be effective for annual and interim periods beginning after December 15, 2017. The Company has not yet selected a transition method and is evaluating the impact the adoption will have on its consolidated financial statements and related disclosures.

Business Acquisitions

9 Months Ended

Sep. 24, 2016

Business Combinations [Abstract]

BUSINESS ACQUISITIONS

Agilux

On September 28, 2016, the Company acquired Agilux Laboratories, Inc. (Agilux), a contract research organization (CRO) that provides a suite of integrated discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic services, and pharmacology services. The acquisition supports the Company’s strategy to offer clients a broader, integrated portfolio that provides services continuously from the earliest stages of drug research through the nonclinical development process. The preliminary purchase price for Agilux was approximately $64.0 million in cash, which is subject to certain customary adjustments, and was funded by borrowings on the Company’s revolving credit facility. The Agilux business will be reported as part of the Company’s DSA reportable segment. Due to the limited time between the acquisition date and the filing of this Quarterly Report on Form 10-Q, it is not practicable for the Company to disclose the preliminary allocation of purchase price to assets acquired and liabilities assumed.

The Company incurred transaction and integration costs of $1.1 million in connection with the acquisition for the three and nine months ended September 24, 2016, which were included in selling, general and administrative expenses.

Blue Stream

On June 27, 2016, the Company acquired Blue Stream Laboratories, Inc. (Blue Stream), an analytical CRO supporting the development of complex biologics and biosimilars. Combining Blue Stream with the Company’s existing discovery, safety assessment, and biologics capabilities creates a leading CRO that has the ability to support biologic and biosimilar development from characterization through clinical testing and commercialization. The preliminary purchase price for Blue Stream was approximately $11.7 million in cash, including $3.0 million in contingent consideration, and is subject to certain customary adjustments. The acquisition was funded by borrowings on the Company’s revolving credit facility. The business is reported in the Company’s Manufacturing reportable segment.

The contingent consideration is a one-time payment that could become payable based on the achievement of a revenue target. If achieved, the payment will become due in the third quarter of the fiscal year 2017. The aggregate, undiscounted amount of contingent consideration that the Company may pay is $3.0 million. The Company estimated the fair value of this contingent consideration based on a probability-weighted set of outcomes.

The purchase price allocation of $11.7 million, net of an insignificant amount of cash acquired, was as follows:



	June 27, 2016
	(in thousands)
Trade receivables (contractual amount of $1,104)	$	1,104
Other current assets (excluding cash)	15
Property, plant and equipment	912
Other long-term assets	187
Definite-lived intangible assets	1,230
Goodwill	10,433
Other current liabilities	(1,133		)
Long-term liabilities	(1,044		)
Total purchase price allocation	$	11,704

The purchase price allocations were prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition.

The breakout of definite-lived intangible assets acquired was as follows:



	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	650	10
Other intangible assets	580		5
Total definite-lived intangible assets	$	1,230	7

The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s Manufacturing business from customers and technology introduced through Blue Stream, the assembled workforce of the acquired business, expected synergies, and the development of future proprietary processes. The goodwill attributable to Blue Stream is not deductible for tax purposes.

Pro forma financial information as well as actual revenue and operating income (loss) have not been included because Blue Stream’s financial results are not significant when compared with the Company’s consolidated financial results.

WIL Research

On April 4, 2016, the Company acquired WIL Research, a provider of safety assessment and CDMO services to biopharmaceutical and agricultural and industrial chemical companies worldwide. The acquisition enhanced the Company’s position as a leading global early-stage CRO by strengthening its ability to partner with clients across the drug discovery and development continuum. The purchase price for WIL Research was approximately $604.8 million, including assumed liabilities of $0.4 million. The purchase price includes payment for estimated working capital, which was subject to final adjustment based on the actual working capital of the acquired business. The acquisition was funded by cash on hand and borrowings on the Company’s amended credit facility. See Note 7, “Long-Term Debt and Capital Lease Obligations.” WIL Research’s safety assessment and CDMO businesses are reported in the Company’s DSA and Manufacturing reportable segments, respectively.

The purchase price allocation of $577.4 million, net of $27.4 million of cash acquired, was as follows:



	April 4, 2016
	(in thousands)
Trade receivables (contractual amount of $48,625)	$	48,157
Inventories	2,296
Other current assets (excluding cash)	4,021
Property, plant and equipment	129,066
Other long-term assets	1,060
Definite-lived intangible assets	165,400
Goodwill	330,229
Deferred revenue	(39,103		)
Other current liabilities	(27,386		)
Long-term liabilities	(36,349		)
Total purchase price allocation	$	577,391

The purchase price allocations were prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. From the date of the acquisition through September 24, 2016, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition.

The breakout of definite-lived intangible assets acquired was as follows:



	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	138,000	15
Developed technology	20,700		3
Backlog	6,700		1
Total definite-lived intangible assets	$	165,400	13

The goodwill resulting from the transaction, $19.0 million of which is deductible for tax purposes due to a prior asset acquisition, is primarily attributed to the potential growth of the Company’s DSA and Manufacturing businesses from clients introduced through WIL Research, the assembled workforce of the acquired business, and expected cost synergies.

The Company incurred transaction and integration costs in connection with the acquisition of $1.3 million and $13.7 million for the three and nine months ended September 24, 2016, respectively, which were included in selling, general and administrative expenses.

WIL Research revenue and operating income for the three months ended September 24, 2016 were $57.4 million and $3.6 million, respectively. WIL Research revenue and operating income for the nine months ended September 24, 2016 were $112.6 million and $4.6 million, respectively, since WIL Research was acquired on April 4, 2016.

The following selected pro forma consolidated results of operations are presented as if the WIL Research acquisition had occurred as of the beginning of the period immediately preceding the period of acquisition after giving effect to certain adjustments. For the nine months ended September 24, 2016, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $1.4 million, reversal of interest expense on borrowings of $2.7 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments. For the nine months ended September 26, 2015, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $5.8 million, reversal of interest expense on borrowings of $8.2 million, inclusion of acquisition-related transaction costs of $9.8 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments.



	Three Months Ended				Nine Months Ended
	September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
Revenue	$	425,720	$	402,744	$	1,275,175	$	1,166,466
Net income attributable to common shareholders	39,530		40,931		129,050		116,863
Earnings per common share
Basic	$	0.84	$	0.88	$	2.75	$	2.51
Diluted	$	0.82	$	0.87	$	2.70	$	2.46

These pro forma results of operations have been prepared for comparative purposes only, and they do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the date indicated or that may result in the future. No effect has been given for synergies, if any, that may have been realized through the acquisition.

Oncotest

On November 18, 2015, the Company acquired Oncotest GmbH (Oncotest), a German CRO providing discovery services for oncology, one of the largest therapeutic areas for biopharmaceutical research and development spending. With this acquisition, the Company expanded its oncology services capabilities, enabling it to provide clients with access to a more comprehensive portfolio of technologies, including patient-derived xenograft (PDX) and syngeneic models. The purchase price for Oncotest was approximately $36.0 million, including $0.3 million in contingent consideration. The acquisition was funded by borrowings on the Company's revolving credit facility. The business is reported in the Company’s DSA reportable segment.

The contingent consideration is a one-time payment that could become payable based on the achievement of a revenue target for the fiscal year 2016. If achieved, the payment will become due in the first quarter of the fiscal year 2017. The aggregate, undiscounted amount of contingent consideration that the Company may pay is €2.0 million ($2.2 million as of September 24, 2016). The Company estimated the fair value of this contingent consideration based on a probability-weighted set of outcomes.

The purchase price allocation of $35.4 million, net of $0.6 million of cash acquired, was as follows:



	November 18, 2015
	(in thousands)
Trade receivables (contractual amount of $3,546)	$	3,520
Inventories	129
Other current assets (excluding cash)	706
Property, plant and equipment	2,528
Definite-lived intangible assets	13,330
Goodwill	22,894
Other long-term assets	250
Current liabilities	(3,456		)
Long-term liabilities	(4,470		)
Total purchase price allocation	$	35,431

The purchase price allocations were prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition.

The breakout of definite-lived intangible assets acquired was as follows:



	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	7,146	19
Developed technology	5,960		19
Other intangible assets	224		3
Total definite-lived intangible assets	$	13,330	19

The goodwill resulting from the transaction is primarily attributed to the potential growth in the Company's DSA businesses from customers and technology introduced through Oncotest, the assembled workforce of the acquired business, and expected cost synergies. The goodwill attributable to Oncotest is not deductible for tax purposes.

The Company incurred insignificant transaction and integration costs in connection with the acquisition for the three and nine months ended September 24, 2016, which were included in selling, general and administrative expenses. During the three and nine months ended September 26, 2015, the Company incurred $0.9 million of transaction and integration costs in connection with the acquisition.

Pro forma financial information as well as actual revenue and operating income (loss) have not been included because Oncotest’s financial results are not significant when compared with the Company’s consolidated financial results.

Celsis

On July 24, 2015, the Company acquired Celsis Group Limited (Celsis), a leading provider of rapid testing systems for non-sterile bacterial contamination for the biopharmaceutical and consumer products industries. The purpose of this acquisition was to enhance the Company’s portfolio of rapid microbial detection products and services with the addition of rapid bioburden testing products. The purchase price for Celsis was $214.5 million, including assumed debt and certain liabilities of $10.3 million. The acquisition was funded by cash on hand and borrowings on the Company’s revolving credit facility. The business is reported in the Company’s Manufacturing reportable segment.

The purchase price allocation of $212.2 million, net of $2.3 million of cash acquired, was as follows:



	July 24, 2015
	(in thousands)
Trade receivables (contractual amount of $5,410)	$	5,288
Inventories	10,103
Other current assets (excluding cash)	13,269
Property, plant and equipment	4,639
Definite-lived intangible assets	118,140
Goodwill	105,550
Other long-term assets	537
Current debt	(9,766		)
Other current liabilities	(7,136		)
Long-term liabilities	(28,388		)
Total purchase price allocation	$	212,236

The breakout of definite-lived intangible assets acquired was as follows:



	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	71,000	16
Developed technology	39,140		14
Trademark and trade names	5,200		14
Non-compete	2,800		5
Total definite-lived intangible assets	$	118,140	15

The goodwill resulting from the transaction is primarily attributed to the potential growth of the Company’s Manufacturing business from clients introduced through Celsis, the assembled workforce of the acquired business, and expected cost synergies. The goodwill attributable to Celsis is not deductible for tax purposes.

The Company incurred insignificant transaction and integration costs in connection with the acquisition for the three and nine months ended September 24, 2016 and transaction and integration costs of $3.9 million and $7.4 million for the three and nine months ended September 26, 2015, respectively, which were included in selling, general and administrative expenses.

Celsis revenue and operating loss for both the three and nine months ended September 26, 2015 were $4.9 million and $3.1 million, respectively, since Celsis was acquired on July 24, 2015. Beginning on July 24, 2015, Celsis has been fully included in the operating results of the Company.

The following selected pro forma consolidated results of operations are presented as if the Celsis acquisition had occurred as of the beginning of the period immediately preceding the period of acquisition after giving effect to certain adjustments, including additional depreciation and amortization of property, plant and equipment, inventory fair value adjustments and intangible assets of $2.4 million for the nine months ended September 26, 2015, and other nonrecurring costs.



	Three Months Ended		Nine Months Ended
	September 26, 2015		September 26, 2015
	(in thousands)
Revenue	$	350,819	$	1,026,643
Net income attributable to common shareholders	40,826		125,863
Earnings per common share
Basic	$	0.88	$	2.70
Diluted	$	0.86	$	2.65

Sunrise

On May 5, 2015, the Company acquired Sunrise Farms, Inc. (Sunrise), a producer of specific-pathogen-free fertile chicken eggs and chickens used in the manufacture of live viruses. The purpose of this business acquisition was to expand the capabilities of the Company’s existing Avian Vaccine Services business. The purchase price of the acquisition was $9.6 million and was funded by cash on hand and borrowings on the Company's revolving credit facility. The business is reported in the Company's Manufacturing reportable segment.

The Company recorded a bargain purchase gain of $9.8 million, which represented the excess of the estimated fair value of the net assets acquired over the preliminary purchase price. The bargain purchase gain was recorded in other income (expense), net, in the Company’s consolidated statement of income and was not recognized for tax purposes. The Company believes there were several factors that contributed to this transaction resulting in a bargain purchase gain, including the highly specialized nature of Sunrise’s business falling outside of the seller’s core activities and a limited pool of potential buyers.

Before recognizing the gain from the bargain purchase, the Company reassessed its initial identification and valuation of assets acquired and liabilities assumed to validate that all assets and liabilities that the Company was able to identify at the acquisition date were properly recognized.

The purchase price allocation of $9.6 million, net of less than $0.1 million of cash acquired, was as follows:



	May 5, 2015
	(in thousands)
Trade receivables (contractual amount of $995)	$	965
Inventories	1,518
Other current assets (excluding cash)	973
Property, plant and equipment	13,698
Definite-lived intangible assets	3,400
Current liabilities	(925		)
Long-term liabilities	(250		)
Fair value of net assets acquired	19,379
Bargain purchase gain	(9,821		)
Total purchase price allocation	$	9,558

The identifiable definite-lived intangible assets acquired represent the client relationships intangible, which is being amortized over the estimated useful life of approximately 15 years.

The Company incurred insignificant transaction and integration costs in connection with the acquisition for the three and nine months ended September 24, 2016, and transaction and integration costs of $0.1 million and $0.7 million during the three and nine months ended September 26, 2015, respectively, which were included in selling, general and administrative expenses.

Pro forma financial information as well as actual revenue and operating income (loss) have not been included because Sunrise’s financial results are not significant when compared with the Company’s consolidated financial results.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Supplemental Balance Sheet Information

9 Months Ended

Sep. 24, 2016

Supplemental Balance Sheet Information [Abstract]

SUPPLEMENTAL BALANCE SHEET INFORMATION

The composition of trade receivables, net is as follows:



	September 24, 2016			December 26, 2015
	(in thousands)
Client receivables	$	278,041		$	230,010
Unbilled revenue	84,754			45,996
Total	362,795			276,006
Less: Allowance for doubtful accounts	(3,061		)	(5,938		)
Trade receivables, net	$	359,734		$	270,068

The composition of inventories is as follows:



	September 24, 2016		December 26, 2015
	(in thousands)
Raw materials and supplies	$	18,445	$	15,998
Work in process	14,119		12,101
Finished products	66,810		65,636
Inventories	$	99,374	$	93,735

The composition of other current assets is as follows:



	September 24, 2016		December 26, 2015
	(in thousands)
Investments	$	7,734	$	20,516
Prepaid income taxes	44,467		26,350
Restricted cash	572		271
Other	148		149
Other current assets	$	52,921	$	47,286

The composition of other assets is as follows:



	September 24, 2016		December 26, 2015
	(in thousands)
Life insurance policies	$	28,837	$	27,554
Venture capital investments	45,653		32,730
Restricted cash	1,825		1,745
Other	10,014		9,614
Other assets	$	86,329	$	71,643

The composition of other current liabilities is as follows:



	September 24, 2016		December 26, 2015
	(in thousands)
Accrued income taxes	$	24,138	$	12,168
Accrued interest and other	993		376
Other current liabilities	$	25,131	$	12,544

The composition of other long-term liabilities is as follows:



	September 24, 2016		December 26, 2015
	(in thousands)
Long-term pension liability	$	32,639	$	34,604
Accrued executive supplemental life insurance retirement plan and deferred compensation plan	31,244		30,188
Other	32,888		24,270
Other long-term liabilities	$	96,771	$	89,062

Venture Capital Investments and Marketable Securities

9 Months Ended

Sep. 24, 2016

Marketable Securities and Equity-Method Affiliates [Abstract]

VENTURE CAPITAL INVESTMENTS AND MARKETABLE SECURITIES

Venture Capital Investments

The Company invests in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. The Company’s ownership interest in these funds ranges from 2.7% to 12.0%. The Company accounts for the investments in limited liability partnerships (LLP), which are variable interest entities, under the equity or cost method of accounting. The Company is not the primary beneficiary because it has no power to direct the activities that most significantly affect the LLPs’ economic performance. The Company accounts for the investments in limited liability companies, which are not variable interest entities, under the equity method of accounting.

The Company’s total commitments to the entities as of September 24, 2016 were $80.6 million, of which the Company funded $35.3 million through September 24, 2016. During the three and nine months ended September 24, 2016, the Company received dividends of $2.3 million from the entities. During the three and nine months ended September 26, 2015, the Company received dividends totaling $5.3 million and $7.3 million, respectively. The Company recognized a gain of $0.4 million and $3.2 million related to these investments for the three months ended September 24, 2016 and September 26, 2015, respectively.

Subsequent to September 24, 2016, the Company invested in a new venture capital fund, which increased the Company’s total commitments by $4.3 million.

Marketable Securities

The Company held no marketable securities as of September 24, 2016.

The following is a summary of the Company's marketable securities as of December 26, 2015, all of which were classified as available-for-sale:



	Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
	(in thousands)
Mutual fund	$	4,650	$	—	$	(141	)	$	4,509
Total	$	4,650	$	—	$	(141	)	$	4,509

During the three and nine months ended September 24, 2016, the Company realized insignificant losses and received proceeds of $4.6 million from the sale of its available-for-sale securities. There were no sales of available-for-sale securities during the nine months ended September 26, 2015.

Fair Value

9 Months Ended

Sep. 24, 2016

Fair Value Disclosures [Abstract]

FAIR VALUE

The Company has certain assets, liabilities, and redeemable noncontrolling interest recorded at fair value, which have been classified as Level 1, 2, or 3 within the fair value hierarchy:


•	Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.


•	Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates.


•	Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

The fair value hierarchy level is determined by asset, liability, and redeemable noncontrolling interest class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the nine months ended September 24, 2016 and September 26, 2015, there were no transfers between levels.

Valuation methodologies used for assets, liabilities, and the redeemable noncontrolling interest measured or disclosed at fair value are as follows:


•	Cash equivalents - Valued at market prices determined through third-party pricing services.


•	Mutual funds - Valued at the unadjusted quoted net asset value of shares held by the Company.


•	Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates.


•	Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments.


•	Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes.


•	Redeemable noncontrolling interest - Valued using the income approach based on estimated future cash flows of the underlying business discounted by a weighted average cost of capital.

Assets, liabilities, and redeemable noncontrolling interest measured at fair value on a recurring basis are summarized below:



	September 24, 2016
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents	$	—	$	14	$	—	$	14
Other assets:
Life insurance policies	—		21,521		—		21,521
Total assets measured at fair value	$	—	$	21,535	$	—	$	21,535

Other current liabilities:
Contingent consideration	$	—	$	—	$	4,126	$	4,126
Total liabilities measured at fair value	$	—	$	—	$	4,126	$	4,126



	December 26, 2015
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents	$	—	$	190	$	—	$	190
Other current assets:
Mutual funds	4,509		—		—		4,509
Foreign currency forward contracts	—		15		—		15
Other assets:
Life insurance policies	—		20,364		—		20,364
Total assets measured at fair value	$	4,509	$	20,569	$	—	$	25,078

Other current liabilities:
Contingent consideration	$	—	$	—	$	1,172	$	1,172
Other long-term liabilities:
Contingent consideration	—		—		198		198
Redeemable noncontrolling interest	—		—		28,008		28,008
Total liabilities and redeemable noncontrolling interest measured at fair value	$	—	$	—	$	29,378	$	29,378

Contingent Consideration

The following table provides a rollforward of the contingent consideration related to the business acquisitions.



	Nine Months Ended
	September 24, 2016			September 26, 2015
	(in thousands)
Beginning balance	$	1,370		$	2,828
Additions	3,600			675
Payments	(874		)	(600		)
Total gains or losses (realized/unrealized):
Reversal of previously recorded contingent liability and change in fair value	30			(1,623		)
Ending balance	$	4,126		$	1,280

The significant unobservable inputs used in the fair value measurement of the Company’s contingent consideration are the probabilities of successful achievement of certain financial targets and a discount rate. Significant increases or decreases in any of the probabilities of success would result in a significantly higher or lower fair value measurement, respectively. Significant increases or decreases in the discount rate would result in a significantly lower or higher fair value measurement, respectively.

Debt Instruments

The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2.

Redeemable Noncontrolling Interest

The Company’s redeemable noncontrolling interest resulted from the acquisition of a 75% ownership interest in Vital River in January 2013. Concurrent with the acquisition, the Company entered into an agreement with the noncontrolling interest holders that provided the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 25% of the entity for cash at its fair value beginning in January 2016.

On July 7, 2016, the Company purchased an additional 12% equity interest in Vital River for $10.8 million, resulting in total ownership of 87%. The Company recorded a $1.6 million gain in equity equal to the excess fair value of the 12% equity interest over the purchase price. Concurrent with the transaction, the original agreement was amended providing the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 13% equity interest at a contractually defined redemption value, subject to a redemption floor (embedded derivative). These rights are exercisable beginning in 2019 and are accelerated in certain events. The Company recorded a charge of $1.5 million in other income (expense), net, equal to the excess fair value of the hybrid instrument (equity interest with an embedded derivative) over the fair value of the 13% equity interest. As of September 24, 2016, the redeemable noncontrolling interest was measured at the greater of the amount that would be paid if settlement occurred at the balance sheet date based on the contractually defined redemption value and its carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 13% interest, the noncontrolling interest is classified in the mezzanine section of the condensed consolidated balance sheet, which is presented above the equity section and below liabilities.

The following table provides a rollforward of the Company’s redeemable noncontrolling interest related to the acquisition of Vital River:



	Redeemable Noncontrolling Interest
	(in thousands)
December 26, 2015 (fair value)	$	28,008
Purchase of 12% equity interest	(12,360		)
Total gains or losses (realized/unrealized):
Net income attributable to noncontrolling interest	462
Foreign currency translation	(875		)
Modification of 13% purchase option	1,495
Change in fair value, included in additional paid-in capital	(1,690		)
September 24, 2016	$	15,040

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Goodwill and Intangible Assets

9 Months Ended

Sep. 24, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

Goodwill

The following table provides a rollforward of the Company’s goodwill:



			Adjustments to Goodwill
	December 26, 2015		Acquisitions		Transfers			Foreign Exchange			September 24, 2016
	(in thousands)
RMS	$	58,167	$	—	$	(342	)	$	(479	)	$	57,346
DSA	247,050		293,973		—			(7,914		)	533,109
Manufacturing	133,612		46,859		342			(7,692		)	173,121
Total	$	438,829	$	340,832	$	—		$	(16,085	)	$	763,576

During the three months ended June 25, 2016, the Company revised the composition of its reportable segments to align with the view of the business following its acquisition of WIL Research. See Note 1, "Basis of Presentation." As a result of this reorganization, goodwill was allocated from the Company's RMS reportable segment to its Manufacturing reportable segment, as shown in the preceding table within "transfers." The allocation was based on the fair value of each business group within its original reporting unit relative to the fair value of that reporting unit. In addition, the Company completed an assessment of any potential goodwill impairment for all reporting units immediately prior to the reallocation and determined that no impairment existed.

Intangible Assets, Net

The following table displays intangible assets, net by major class:



	September 24, 2016							December 26, 2015
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
	(in thousands)
Backlog	$	8,645	$	(4,979	)	$	3,666	$	50,568	$	(50,554	)	$	14
Technology	74,304		(11,910		)	62,394		60,350		(5,911		)	54,439
Trademarks and trade names	8,439		(4,029		)	4,410		11,495		(5,944		)	5,551
Other	12,390		(5,159		)	7,231		14,711		(7,285		)	7,426
Other intangible assets	103,778		(26,077		)	77,701		137,124		(69,694		)	67,430
Client relationships	518,050		(199,299		)	318,751		396,537		(183,163		)	213,374
Intangible assets	$	621,828	$	(225,376	)	$	396,452	$	533,661	$	(252,857	)	$	280,804

During the three months ended March 26, 2016, the Company determined that the carrying values of certain DSA intangible assets were not recoverable and recorded an impairment charge of $1.9 million, which was included in costs of services provided (excluding amortization of intangible assets).

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Long-Term Debt and Capital Lease Obligations

9 Months Ended

Sep. 24, 2016

Debt Disclosure [Abstract]

LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS

Long-Term Debt

Long-term debt, net consists of the following:



	September 24, 2016			December 26, 2015
	(in thousands)
Term loans	$	641,875		$	390,000
Revolving credit facility	596,329			446,041
Other long-term debt	197			193
Total debt	1,238,401			836,234
Less: current portion of long-term debt	(24,572		)	(15,193		)
Long-term debt	1,213,829			821,041
Debt discount and debt issuance costs	(8,139		)	(6,805		)
Long-term debt, net	$	1,205,690		$	814,236

As of September 24, 2016 and December 26, 2015, the weighted average interest rate on the Company’s debt was 1.95% and 1.33%, respectively.

In April 2015, the Company amended and restated the $970M Credit Facility, creating a $1.3 billion facility ($1.3B Credit Facility) that provided for a $400.0 million term loan and a $900.0 million multi-currency revolving facility. The interest rates applicable to term loans and revolving loans under the Company’s $1.3B Credit Facility were, at the Company’s option, equal to either the alternate base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.5% or (3) the one-month adjusted LIBOR rate plus 1%), or the adjusted LIBOR rate plus an interest rate margin based upon the Company’s leverage ratio.

On March 30, 2016, the Company amended and restated its $1.3B credit facility creating a $1.65 billion credit facility ($1.65B Credit Facility) which (1) extends the maturity date for the credit facility and (2) makes certain other amendments in connection with the Company’s acquisition of WIL Research. The amendment was accounted for as a debt modification with a partial extinguishment of debt. In connection with the transaction, the Company has capitalized approximately $3.3 million and expensed approximately $1.4 million of debt issuance costs.

The $1.65B Credit Facility provides for a $650.0 million term loan and a $1.0 billion multi-currency revolving facility. The term loan facility matures in 19 quarterly installments with the last installment due March 30, 2021. The revolving facility matures on March 30, 2021, and requires no scheduled payment before that date. Under specified circumstances, the Company has the ability to increase the term loan and/or revolving line of credit by up to $500 million in the aggregate.

The interest rates applicable to term loan and revolving loans under the $1.65B Credit Facility are, at the Company’s option, equal to either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted LIBOR rate plus 1%) or the adjusted LIBOR rate plus an interest rate margin based upon the Company’s leverage ratio.

The $1.65B Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to the Company’s business and negative and affirmative covenants. These covenants include (1) maintenance of a ratio of consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) less capital expenditures to consolidated cash interest expense, for any period of four consecutive fiscal quarters, of no less than 3.50 to 1.0 as well as (2) maintenance of a ratio of consolidated indebtedness to consolidated EBITDA for any period of four consecutive fiscal quarters, of no more than 4.25 to 1.0 with step downs to 3.50 to 1.0 by the last day of the three months ended December 30, 2017. As of September 24, 2016, the Company was compliant with all covenants.

The obligations of the Company under the $1.65B Credit Facility are collateralized by substantially all of the assets of the Company.

Letters of Credit

As of September 24, 2016 and December 26, 2015, the Company had $5.1 million and $4.9 million in outstanding letters of credit, respectively.

Capital Lease Obligations

The Company’s capital lease obligations amounted to $28.9 million and $33.6 million as of September 24, 2016 and December 26, 2015, respectively.

Equity

9 Months Ended

Sep. 24, 2016

Equity [Abstract]

EQUITY

Earnings Per Share

The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:



	Three Months Ended					Nine Months Ended
	September 24, 2016		September 26, 2015			September 24, 2016		September 26, 2015
	(in thousands)
Numerator:
Income from continuing operations, net of income taxes	$	37,691	$	37,901		$	110,811	$	118,774
Income (loss) from discontinued operations, net of income taxes	342		(34		)	328		(48		)
Less: Net income attributable to noncontrolling interests	298		488			1,054		1,297
Net income attributable to common shareholders	$	37,735	$	37,379		$	110,085	$	117,429

Denominator:
Weighted-average shares outstanding - Basic	47,160		46,290			46,954		46,572
Effect of dilutive securities:
Stock options, restricted stock units, performance share units and restricted stock	874		955			884		1,012
Weighted-average shares outstanding - Diluted	48,034		47,245			47,838		47,584

Options to purchase approximately 0.6 million and 0.5 million shares for the three months ended September 24, 2016 and September 26, 2015, respectively, as well as an insignificant number of restricted stock, restricted stock units (RSUs), and performance share units (PSUs), were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Options to purchase approximately 0.9 million and 0.5 million shares for the nine months ended September 24, 2016 and September 26, 2015, respectively, as well as an insignificant number of restricted stock, RSUs, and PSUs, were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Basic weighted average shares outstanding for both the nine months ended September 24, 2016 and September 26, 2015 excluded the impact of approximately 1.1 million shares of non-vested restricted stock and restricted stock units.

Treasury Shares

During the nine months ended September 24, 2016, the Company did not repurchase any shares under its authorized stock repurchase program. The Company repurchased approximately 1.5 million shares for $108.8 million in the nine months ended September 26, 2015. As of September 24, 2016, the Company had $69.7 million remaining on the authorized stock repurchase program. The Company’s stock-based compensation plans permit the netting of common stock upon vesting of restricted stock, RSUs, and PSUs in order to satisfy individual minimum statutory tax withholding requirements. During the nine months ended September 24, 2016 and September 26, 2015, the Company acquired approximately 0.2 million shares for $12.2 million and approximately 0.1 million shares for $8.7 million, respectively.

Accumulated Other Comprehensive Income

Changes to each component of accumulated other comprehensive income, net of income taxes, are as follows:



	Foreign Currency Translation Adjustment and Other			Pension and Other Post-Retirement Benefit Plans			Total
	(in thousands)
December 26, 2015	$	(82,977	)	$	(52,571	)	$	(135,548	)
Other comprehensive loss before reclassifications	(31,735		)	—			(31,735		)
Amounts reclassified from accumulated other comprehensive income (loss)	—			1,961			1,961
Net current period other comprehensive income	(31,735		)	1,961			(29,774		)
Income tax expense	—			424			424
September 24, 2016	$	(114,712	)	$	(51,034	)	$	(165,746	)

Foreign currency translation and other includes an insignificant amount of unrealized gains (losses) on available-for-sale marketable securities.

Nonredeemable Noncontrolling Interests

The Company has investments in several entities whose financial results are consolidated in the Company’s financial statements, as it has a controlling financial interest in these entities. The interests of the respective noncontrolling parties in these entities have been recorded as noncontrolling interests. The activity within the nonredeemable noncontrolling interests was insignificant during the three and nine months ended September 24, 2016 and September 26, 2015.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Income Taxes	9 Months Ended
Income Taxes	Sep. 24, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rate for the three months ended September 24, 2016 and September 26, 2015 was 29.2% and 28.7%, respectively. The Company’s effective tax rate was 30.4% and 18.3% for the nine months ended September 24, 2016 and September 26, 2015, respectively. For the three months ended September 24, 2016, the increase was primarily attributable to the accrual of withholding taxes in order to access cash from the Company’s Canadian and Chinese operations for use outside of the U.S. and an unbenefited loss due to a site closure, offset by a $1.4 million tax benefit as a result of an enacted U.K. tax law change and favorability from the amount and mix of earnings. For the nine months ended September 24, 2016, the increase reflects the items above as well as a prior year reduction in unrecognized tax benefits and related interest of $10.4 million due to the expiration of the statute of limitations associated with pre-acquisition tax positions on forgiveness of debt and a prior year non-taxable bargain purchase gain of $9.9 million associated with the acquisition of Sunrise. During the three months ended September 24, 2016, the Company’s unrecognized tax benefits increased by $0.2 million to $25.5 million, primarily due to an additional quarter of Canadian Scientific Research and Experimental Development credit reserves offset by the expiration of the statute of limitations on federal reserves. The amount of unrecognized income tax benefits that would impact the effective tax rate stayed constant at $22.2 million. The amount of accrued interest and penalties on unrecognized tax benefits was $1.6 million and $0.2 million, respectively, at September 24, 2016. The Company estimates that it is reasonably possible that the unrecognized tax benefits will decrease by up to $3.5 million over the next twelve-month period, primarily as a result of the outcome of a pending tax ruling and competent authority proceedings. The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits in jurisdictions including the U.S., U.K., China, Japan, France, Germany, and Canada. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2013. The Company and certain of its subsidiaries have ongoing tax controversies with various tax authorities in the U.S., Canada, China, and France. The Company does not believe that resolution of these controversies will have a material impact on its financial position or results of operations. In accordance with the Company’s policy, the remaining undistributed earnings of its non-U.S. subsidiaries remain indefinitely reinvested as of September 24, 2016, as they are required to fund needs outside the U.S. and cannot be repatriated in a manner that is substantially tax free. Income tax expense related to change in unrecognized pension gains, losses, and prior service costs was $0.1 million and $0.2 million for the three months ended September 24, 2016 and September 26, 2015, respectively. Income tax expense related to changes in unrecognized pension gains, losses, and prior service costs was $0.4 million and $0.7 million for the nine months ended September 24, 2016 and September 26, 2015, respectively.

Pension and Other Post-Retirement Benefit Plans

9 Months Ended

Sep. 24, 2016

Compensation and Retirement Disclosure [Abstract]

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS

The following table provides the components of net periodic cost for the Company’s pension plans for the three months ended September 24, 2016 and September 26, 2015:



	Pension Plans
	September 24, 2016			September 26, 2015
	(in thousands)
Service cost	$	655		$	1,149
Interest cost	2,773			3,335
Expected return on plan assets	(3,038		)	(4,383		)
Amortization of prior service benefit	(142		)	(150		)
Amortization of net loss	503			845
Settlements	788			—
Net periodic cost	$	1,539		$	796

The following table provides the components of net periodic cost for the Company’s pension plans for the nine months ended September 24, 2016 and September 26, 2015:



	Pension Plans
	September 24, 2016			September 26, 2015
	(in thousands)
Service cost	$	1,848		$	3,448
Interest cost	9,357			10,006
Expected return on plan assets	(11,028		)	(13,147		)
Amortization of prior service benefit	(430		)	(451		)
Amortization of net loss	1,594			2,636
Settlements	788			—
Net periodic cost	$	2,129		$	2,492

The net periodic cost for the Company’s post-retirement benefit plan for the three and nine months ended September 24, 2016 and September 26, 2015 was insignificant.

Stock-Based Compensation

9 Months Ended

Sep. 24, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

The Company has stock-based compensation plans under which employees and non-employee directors may be granted stock-based awards such as stock options, restricted stock, RSUs, and PSUs.

The following table provides stock-based compensation by the financial statement line item in which it is reflected:



	Three Months Ended						Nine Months Ended
	September 24, 2016			September 26, 2015			September 24, 2016			September 26, 2015
	(in thousands)
Cost of revenue	$	1,608		$	1,670		$	4,957		$	4,959
Selling, general and administrative	8,992			8,806			27,690			25,390
Stock-based compensation, before income taxes	10,600			10,476			32,647			30,349
Provision for income taxes	(3,785		)	(3,733		)	(11,653		)	(10,737		)
Stock-based compensation, net of income taxes	$	6,815		$	6,743		$	20,994		$	19,612

During the nine months ended September 24, 2016, the Company issued approximately 0.6 million stock options with a per share weighted average grant date fair value of $15.12, approximately 0.2 million RSUs with a per share weighted average grant date fair value of $75.13, and approximately 0.2 million PSUs with a per share weighted average grant date fair value of $79.81. The maximum number of common shares to be issued upon vesting of PSUs granted during the nine months ended September 24, 2016 is approximately 0.4 million.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Foreign Currency Contracts

9 Months Ended

Sep. 24, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

FOREIGN CURRENCY CONTRACTS

The Company enters into foreign exchange forward contracts to limit its foreign currency exposure related to intercompany loans that are not of a long-term investment nature. These contracts are recorded at fair value in the Company’s condensed consolidated balance sheet and are not designated as hedging instruments. Any gains or losses on such contracts are immediately recognized in other income (expense), net, and are largely offset by the remeasurement of the underlying intercompany loan balances.

The notional amount and fair value of the Company’s foreign currency forward contracts at December 26, 2015 was as follows:



Notional Amount		Fair Value		Balance Sheet Location
(in thousands)
$	88,483	$	15	Other Current Assets

No foreign currency contracts were open as of September 24, 2016.

The following table summarizes gains recognized on foreign exchange forward contracts related to intercompany loans denominated in British Pounds and Euros on the Company’s consolidated statement of income:



	Three Months Ended					Nine Months Ended
Location of Gain (Loss)	September 24, 2016		September 26, 2015			September 24, 2016		September 26, 2015
	(in thousands)
Other income (expense), net	$	—	$	(3,194	)	$	3,373	$	(3,194	)

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 24, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation Various lawsuits, claims and proceedings of a nature considered normal to its business are pending against the Company. While the outcome of any of these proceedings cannot be accurately predicted, the Company does not believe the ultimate resolution of any of these existing matters would have a material adverse effect on the Company’s business or financial condition. In July 2015, IDEXX Laboratories, Inc. and IDEXX Distribution, Inc. (collectively, IDEXX) filed a complaint in the United States District Court for the District of Delaware alleging the Company has infringed three recently issued patents related to a blood spot sample collection method used in determining the presence or absence of an infectious disease in a population of rodents. On September 21, 2015, the Company timely filed a motion to dismiss the complaint on the grounds that all of the claims are directed to unpatentable subject matter and therefore are invalid. On October 7, 2015, IDEXX filed an amended complaint, which substantially asserted the same patents and infringement allegations as asserted in the original complaint, and on October 26, 2015, the Company timely filed a motion to dismiss this amended complaint. The hearing on the motion to dismiss was held on January 12, 2016. On July 1, 2016, the Court issued an opinion denying the motion to dismiss. The Company filed its answer to the complaint on July 21, 2016. In addition, on July 29, 2016, the Company initiated an inter partes review (IPR) procedure with the United States Patent and Trademark Office challenging the validity of the IDEXX patents. While no prediction may be made as to the outcome of litigation or the IPR, the Company intends to defend against this proceeding vigorously and therefore an estimate of the possible loss or range of loss cannot be made. In May 2013, the Company commenced an investigation into inaccurate billing with respect to certain government contracts. The Company promptly reported these matters to the relevant government contracting officers, the Department of Health and Human Services’ Office of the Inspector General, and the Department of Justice, and the Company is cooperating with these agencies to ensure the proper repayment and resolution of this matter. The Company previously identified approximately $1.5 million of excess amounts billed on these contracts since January 1, 2007, and recorded a liability for such amount. Based on its ongoing discussions with the government, the Company has recorded an additional charge of $0.3 million during the three months ended September 24, 2016. The Company’s best estimate, which totals $1.8 million, may be subject to change based on the terms of any final settlement with the Department of Justice and the Department of Health and Human Services’ Office of the Inspector General. Lease Commitments During the nine months ended September 24, 2016, the Company assumed or entered into new lease agreements or exercised options to extend the lease terms for certain existing leases. As a result, the Company’s lease obligations through September 24, 2016 increased by $22.5 million.

Segment Information

9 Months Ended

Sep. 24, 2016

Segment Reporting [Abstract]

SEGMENT INFORMATION

The Company revised the composition of its reportable segments during the three months ended June 25, 2016. See Note 1, “Basis of Presentation.” The Company reported segment results on this basis retrospectively for all comparable prior periods presented.

The following table presents revenue and other financial information by reportable segment:



	Three Months Ended				Nine Months Ended
	September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
RMS
Revenue	$	120,928	$	117,894	$	369,325	$	356,570
Operating income	31,224		31,427		103,055		93,581
Depreciation and amortization	5,245		5,279		15,613		16,590
Capital expenditures	2,532		3,022		5,966		12,111
DSA
Revenue	$	215,817	$	158,272	$	594,859	$	451,659
Operating income	31,303		33,191		94,514		84,856
Depreciation and amortization	20,671		11,509		51,228		35,060
Capital expenditures	4,509		4,277		13,860		13,756
Manufacturing
Revenue	$	88,975	$	73,299	$	250,459	$	201,223
Operating income	26,711		18,491		73,447		55,872
Depreciation and amortization	6,181		5,179		18,682		12,156
Capital expenditures	1,862		2,139		8,247		5,475

For the three months ended September 24, 2016 and September 26, 2015, reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts are as follows:



	Operating Income						Depreciation and Amortization				Capital Expenditures
	September 24, 2016			September 26, 2015			September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
Total reportable segments	$	89,238		$	83,109		$	32,097	$	21,967	$	8,903	$	9,438
Unallocated corporate	(30,443		)	(27,669		)	2,011		1,847		665		1,014
Total consolidated	$	58,795		$	55,440		$	34,108	$	23,814	$	9,568	$	10,452

For the nine months ended September 24, 2016 and September 26, 2015, reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts are as follows:



	Operating Income						Depreciation and Amortization				Capital Expenditures
	September 24, 2016			September 26, 2015			September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
Total reportable segments	$	271,016		$	234,309		$	85,523	$	63,806	$	28,073	$	31,342
Unallocated corporate	(102,688		)	(80,129		)	5,593		5,524		1,536		3,666
Total consolidated	$	168,328		$	154,180		$	91,116	$	69,330	$	29,609	$	35,008

Revenue for each significant product or service offering is as follows:



	Three Months Ended				Nine Months Ended
	September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
RMS	$	120,928	$	117,894	$	369,325	$	356,570
DSA	215,817		158,272		594,859		451,659
Manufacturing	88,975		73,299		250,459		201,223
Total revenue	$	425,720	$	349,465	$	1,214,643	$	1,009,452

A summary of unallocated corporate expense consists of the following:



	Three Months Ended				Nine Months Ended
	September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
Stock-based compensation	$	6,739	$	6,802	$	20,593	$	19,501
Compensation, benefits, and other employee-related expenses	9,048		6,821		29,327		24,751
External consulting and other service expenses	4,545		4,280		16,377		11,051
Information Technology	2,903		2,618		8,399		6,167
Depreciation	2,011		1,847		5,593		5,524
Acquisition and integration	2,033		3,478		13,056		7,072
Other general unallocated corporate	3,164		1,823		9,343		6,063
Total unallocated corporate expense	$	30,443	$	27,669	$	102,688	$	80,129

Other general unallocated corporate expense consists of various departmental costs including those associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Basis of Presentation - Significant Accounting Policies (Policies)

9 Months Ended

Sep. 24, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Fiscal Period

Segment Reporting

The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

The revised reportable segments are as follows:



Research Models and Services	Discovery and Safety Assessment	Manufacturing Support
Research Models	Discovery Services	Microbial Solutions
Research Model Services	Safety Assessment	Avian
		Biologics
		Contract Manufacturing

Use of Estimates

Consolidation

Newly Issued Accounting Pronouncements

Basis of Presentation (Tables)

9 Months Ended

Sep. 24, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Reportable Segments

The revised reportable segments are as follows:



Research Models and Services	Discovery and Safety Assessment	Manufacturing Support
Research Models	Discovery Services	Microbial Solutions
Research Model Services	Safety Assessment	Avian
		Biologics
		Contract Manufacturing

The following table presents revenue and other financial information by reportable segment:



	Three Months Ended				Nine Months Ended
	September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
RMS
Revenue	$	120,928	$	117,894	$	369,325	$	356,570
Operating income	31,224		31,427		103,055		93,581
Depreciation and amortization	5,245		5,279		15,613		16,590
Capital expenditures	2,532		3,022		5,966		12,111
DSA
Revenue	$	215,817	$	158,272	$	594,859	$	451,659
Operating income	31,303		33,191		94,514		84,856
Depreciation and amortization	20,671		11,509		51,228		35,060
Capital expenditures	4,509		4,277		13,860		13,756
Manufacturing
Revenue	$	88,975	$	73,299	$	250,459	$	201,223
Operating income	26,711		18,491		73,447		55,872
Depreciation and amortization	6,181		5,179		18,682		12,156
Capital expenditures	1,862		2,139		8,247		5,475

Business Acquisitions (Tables)

9 Months Ended

Sep. 24, 2016

Business Combinations [Abstract]

Schedule of Business Acquisitions, by Acquisition

The purchase price allocation of $212.2 million, net of $2.3 million of cash acquired, was as follows:



	July 24, 2015
	(in thousands)
Trade receivables (contractual amount of $5,410)	$	5,288
Inventories	10,103
Other current assets (excluding cash)	13,269
Property, plant and equipment	4,639
Definite-lived intangible assets	118,140
Goodwill	105,550
Other long-term assets	537
Current debt	(9,766		)
Other current liabilities	(7,136		)
Long-term liabilities	(28,388		)
Total purchase price allocation	$	212,236

The purchase price allocation of $9.6 million, net of less than $0.1 million of cash acquired, was as follows:



	May 5, 2015
	(in thousands)
Trade receivables (contractual amount of $995)	$	965
Inventories	1,518
Other current assets (excluding cash)	973
Property, plant and equipment	13,698
Definite-lived intangible assets	3,400
Current liabilities	(925		)
Long-term liabilities	(250		)
Fair value of net assets acquired	19,379
Bargain purchase gain	(9,821		)
Total purchase price allocation	$	9,558

The purchase price allocation of $577.4 million, net of $27.4 million of cash acquired, was as follows:



	April 4, 2016
	(in thousands)
Trade receivables (contractual amount of $48,625)	$	48,157
Inventories	2,296
Other current assets (excluding cash)	4,021
Property, plant and equipment	129,066
Other long-term assets	1,060
Definite-lived intangible assets	165,400
Goodwill	330,229
Deferred revenue	(39,103		)
Other current liabilities	(27,386		)
Long-term liabilities	(36,349		)
Total purchase price allocation	$	577,391

The purchase price allocation of $35.4 million, net of $0.6 million of cash acquired, was as follows:



	November 18, 2015
	(in thousands)
Trade receivables (contractual amount of $3,546)	$	3,520
Inventories	129
Other current assets (excluding cash)	706
Property, plant and equipment	2,528
Definite-lived intangible assets	13,330
Goodwill	22,894
Other long-term assets	250
Current liabilities	(3,456		)
Long-term liabilities	(4,470		)
Total purchase price allocation	$	35,431

The purchase price allocation of $11.7 million, net of an insignificant amount of cash acquired, was as follows:



	June 27, 2016
	(in thousands)
Trade receivables (contractual amount of $1,104)	$	1,104
Other current assets (excluding cash)	15
Property, plant and equipment	912
Other long-term assets	187
Definite-lived intangible assets	1,230
Goodwill	10,433
Other current liabilities	(1,133		)
Long-term liabilities	(1,044		)
Total purchase price allocation	$	11,704

Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination

The breakout of definite-lived intangible assets acquired was as follows:



	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	71,000	16
Developed technology	39,140		14
Trademark and trade names	5,200		14
Non-compete	2,800		5
Total definite-lived intangible assets	$	118,140	15

The breakout of definite-lived intangible assets acquired was as follows:



	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	7,146	19
Developed technology	5,960		19
Other intangible assets	224		3
Total definite-lived intangible assets	$	13,330	19

The breakout of definite-lived intangible assets acquired was as follows:



	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	138,000	15
Developed technology	20,700		3
Backlog	6,700		1
Total definite-lived intangible assets	$	165,400	13

The breakout of definite-lived intangible assets acquired was as follows:



	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	650	10
Other intangible assets	580		5
Total definite-lived intangible assets	$	1,230	7

Business Acquisition, Pro Forma Information



	Three Months Ended				Nine Months Ended
	September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
Revenue	$	425,720	$	402,744	$	1,275,175	$	1,166,466
Net income attributable to common shareholders	39,530		40,931		129,050		116,863
Earnings per common share
Basic	$	0.84	$	0.88	$	2.75	$	2.51
Diluted	$	0.82	$	0.87	$	2.70	$	2.46



	Three Months Ended		Nine Months Ended
	September 26, 2015		September 26, 2015
	(in thousands)
Revenue	$	350,819	$	1,026,643
Net income attributable to common shareholders	40,826		125,863
Earnings per common share
Basic	$	0.88	$	2.70
Diluted	$	0.86	$	2.65

Supplemental Balance Sheet Information (Tables)

9 Months Ended

Sep. 24, 2016

Supplemental Balance Sheet Information [Abstract]

Composition of Net Trade Receivables

The composition of trade receivables, net is as follows:



	September 24, 2016			December 26, 2015
	(in thousands)
Client receivables	$	278,041		$	230,010
Unbilled revenue	84,754			45,996
Total	362,795			276,006
Less: Allowance for doubtful accounts	(3,061		)	(5,938		)
Trade receivables, net	$	359,734		$	270,068

Composition of Inventories

The composition of inventories is as follows:



	September 24, 2016		December 26, 2015
	(in thousands)
Raw materials and supplies	$	18,445	$	15,998
Work in process	14,119		12,101
Finished products	66,810		65,636
Inventories	$	99,374	$	93,735

Composition of Other Current Assets

The composition of other current assets is as follows:



	September 24, 2016		December 26, 2015
	(in thousands)
Investments	$	7,734	$	20,516
Prepaid income taxes	44,467		26,350
Restricted cash	572		271
Other	148		149
Other current assets	$	52,921	$	47,286

Composition of Other Assets

The composition of other assets is as follows:



	September 24, 2016		December 26, 2015
	(in thousands)
Life insurance policies	$	28,837	$	27,554
Venture capital investments	45,653		32,730
Restricted cash	1,825		1,745
Other	10,014		9,614
Other assets	$	86,329	$	71,643

Composition of Other Current Liabilities

The composition of other current liabilities is as follows:



	September 24, 2016		December 26, 2015
	(in thousands)
Accrued income taxes	$	24,138	$	12,168
Accrued interest and other	993		376
Other current liabilities	$	25,131	$	12,544

Composition of Other Long-Term Liabilities

The composition of other long-term liabilities is as follows:



	September 24, 2016		December 26, 2015
	(in thousands)
Long-term pension liability	$	32,639	$	34,604
Accrued executive supplemental life insurance retirement plan and deferred compensation plan	31,244		30,188
Other	32,888		24,270
Other long-term liabilities	$	96,771	$	89,062

Venture Capital Investments and Marketable Securities (Tables)

9 Months Ended

Sep. 24, 2016

Marketable Securities and Equity-Method Affiliates [Abstract]

Schedule of Available-for-sale Securities Reconciliation

The following is a summary of the Company's marketable securities as of December 26, 2015, all of which were classified as available-for-sale:



	Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
	(in thousands)
Mutual fund	$	4,650	$	—	$	(141	)	$	4,509
Total	$	4,650	$	—	$	(141	)	$	4,509

Fair Value (Tables)

9 Months Ended

Sep. 24, 2016

Fair Value Disclosures [Abstract]

Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis

Assets, liabilities, and redeemable noncontrolling interest measured at fair value on a recurring basis are summarized below:



	September 24, 2016
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents	$	—	$	14	$	—	$	14
Other assets:
Life insurance policies	—		21,521		—		21,521
Total assets measured at fair value	$	—	$	21,535	$	—	$	21,535

Other current liabilities:
Contingent consideration	$	—	$	—	$	4,126	$	4,126
Total liabilities measured at fair value	$	—	$	—	$	4,126	$	4,126



	December 26, 2015
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents	$	—	$	190	$	—	$	190
Other current assets:
Mutual funds	4,509		—		—		4,509
Foreign currency forward contracts	—		15		—		15
Other assets:
Life insurance policies	—		20,364		—		20,364
Total assets measured at fair value	$	4,509	$	20,569	$	—	$	25,078

Other current liabilities:
Contingent consideration	$	—	$	—	$	1,172	$	1,172
Other long-term liabilities:
Contingent consideration	—		—		198		198
Redeemable noncontrolling interest	—		—		28,008		28,008
Total liabilities and redeemable noncontrolling interest measured at fair value	$	—	$	—	$	29,378	$	29,378

Fair Value, Contingent Consideration

The following table provides a rollforward of the contingent consideration related to the business acquisitions.



	Nine Months Ended
	September 24, 2016			September 26, 2015
	(in thousands)
Beginning balance	$	1,370		$	2,828
Additions	3,600			675
Payments	(874		)	(600		)
Total gains or losses (realized/unrealized):
Reversal of previously recorded contingent liability and change in fair value	30			(1,623		)
Ending balance	$	4,126		$	1,280

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The following table provides a rollforward of the Company’s redeemable noncontrolling interest related to the acquisition of Vital River:



	Redeemable Noncontrolling Interest
	(in thousands)
December 26, 2015 (fair value)	$	28,008
Purchase of 12% equity interest	(12,360		)
Total gains or losses (realized/unrealized):
Net income attributable to noncontrolling interest	462
Foreign currency translation	(875		)
Modification of 13% purchase option	1,495
Change in fair value, included in additional paid-in capital	(1,690		)
September 24, 2016	$	15,040

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 24, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in the Gross Carrying Amount and Accumulated Amortization of Goodwill

The following table provides a rollforward of the Company’s goodwill:



			Adjustments to Goodwill
	December 26, 2015		Acquisitions		Transfers			Foreign Exchange			September 24, 2016
	(in thousands)
RMS	$	58,167	$	—	$	(342	)	$	(479	)	$	57,346
DSA	247,050		293,973		—			(7,914		)	533,109
Manufacturing	133,612		46,859		342			(7,692		)	173,121
Total	$	438,829	$	340,832	$	—		$	(16,085	)	$	763,576

Schedule of Finite-Lived Intangible Assets

The following table displays intangible assets, net by major class:



	September 24, 2016							December 26, 2015
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
	(in thousands)
Backlog	$	8,645	$	(4,979	)	$	3,666	$	50,568	$	(50,554	)	$	14
Technology	74,304		(11,910		)	62,394		60,350		(5,911		)	54,439
Trademarks and trade names	8,439		(4,029		)	4,410		11,495		(5,944		)	5,551
Other	12,390		(5,159		)	7,231		14,711		(7,285		)	7,426
Other intangible assets	103,778		(26,077		)	77,701		137,124		(69,694		)	67,430
Client relationships	518,050		(199,299		)	318,751		396,537		(183,163		)	213,374
Intangible assets	$	621,828	$	(225,376	)	$	396,452	$	533,661	$	(252,857	)	$	280,804

Long-Term Debt and Capital Lease Obligations (Tables)

9 Months Ended

Sep. 24, 2016

Debt Disclosure [Abstract]

Schedule of Debt

Long-term debt, net consists of the following:



	September 24, 2016			December 26, 2015
	(in thousands)
Term loans	$	641,875		$	390,000
Revolving credit facility	596,329			446,041
Other long-term debt	197			193
Total debt	1,238,401			836,234
Less: current portion of long-term debt	(24,572		)	(15,193		)
Long-term debt	1,213,829			821,041
Debt discount and debt issuance costs	(8,139		)	(6,805		)
Long-term debt, net	$	1,205,690		$	814,236

Equity (Tables)

9 Months Ended

Sep. 24, 2016

Equity [Abstract]

Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings Per Share

The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:



	Three Months Ended					Nine Months Ended
	September 24, 2016		September 26, 2015			September 24, 2016		September 26, 2015
	(in thousands)
Numerator:
Income from continuing operations, net of income taxes	$	37,691	$	37,901		$	110,811	$	118,774
Income (loss) from discontinued operations, net of income taxes	342		(34		)	328		(48		)
Less: Net income attributable to noncontrolling interests	298		488			1,054		1,297
Net income attributable to common shareholders	$	37,735	$	37,379		$	110,085	$	117,429

Denominator:
Weighted-average shares outstanding - Basic	47,160		46,290			46,954		46,572
Effect of dilutive securities:
Stock options, restricted stock units, performance share units and restricted stock	874		955			884		1,012
Weighted-average shares outstanding - Diluted	48,034		47,245			47,838		47,584

Schedule of Accumulated Other Comprehensive Income

Changes to each component of accumulated other comprehensive income, net of income taxes, are as follows:



	Foreign Currency Translation Adjustment and Other			Pension and Other Post-Retirement Benefit Plans			Total
	(in thousands)
December 26, 2015	$	(82,977	)	$	(52,571	)	$	(135,548	)
Other comprehensive loss before reclassifications	(31,735		)	—			(31,735		)
Amounts reclassified from accumulated other comprehensive income (loss)	—			1,961			1,961
Net current period other comprehensive income	(31,735		)	1,961			(29,774		)
Income tax expense	—			424			424
September 24, 2016	$	(114,712	)	$	(51,034	)	$	(165,746	)

Pension and Other Post-Retirement Benefit Plans Employee Benefits (Tables)

9 Months Ended

Sep. 24, 2016

Compensation and Retirement Disclosure [Abstract]

Schedule of Net Costs (Benefits)

The following table provides the components of net periodic cost for the Company’s pension plans for the three months ended September 24, 2016 and September 26, 2015:



	Pension Plans
	September 24, 2016			September 26, 2015
	(in thousands)
Service cost	$	655		$	1,149
Interest cost	2,773			3,335
Expected return on plan assets	(3,038		)	(4,383		)
Amortization of prior service benefit	(142		)	(150		)
Amortization of net loss	503			845
Settlements	788			—
Net periodic cost	$	1,539		$	796

The following table provides the components of net periodic cost for the Company’s pension plans for the nine months ended September 24, 2016 and September 26, 2015:



	Pension Plans
	September 24, 2016			September 26, 2015
	(in thousands)
Service cost	$	1,848		$	3,448
Interest cost	9,357			10,006
Expected return on plan assets	(11,028		)	(13,147		)
Amortization of prior service benefit	(430		)	(451		)
Amortization of net loss	1,594			2,636
Settlements	788			—
Net periodic cost	$	2,129		$	2,492

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 24, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock-Based Compensation Expense

The following table provides stock-based compensation by the financial statement line item in which it is reflected:



	Three Months Ended						Nine Months Ended
	September 24, 2016			September 26, 2015			September 24, 2016			September 26, 2015
	(in thousands)
Cost of revenue	$	1,608		$	1,670		$	4,957		$	4,959
Selling, general and administrative	8,992			8,806			27,690			25,390
Stock-based compensation, before income taxes	10,600			10,476			32,647			30,349
Provision for income taxes	(3,785		)	(3,733		)	(11,653		)	(10,737		)
Stock-based compensation, net of income taxes	$	6,815		$	6,743		$	20,994		$	19,612

Foreign Currency Contracts (Tables)

9 Months Ended

Sep. 24, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Foreign Currency Contracts

The notional amount and fair value of the Company’s foreign currency forward contracts at December 26, 2015 was as follows:



Notional Amount		Fair Value		Balance Sheet Location
(in thousands)
$	88,483	$	15	Other Current Assets

Derivative Instruments, Gain (Loss)



	Three Months Ended					Nine Months Ended
Location of Gain (Loss)	September 24, 2016		September 26, 2015			September 24, 2016		September 26, 2015
	(in thousands)
Other income (expense), net	$	—	$	(3,194	)	$	3,373	$	(3,194	)

Segment Information (Tables)

9 Months Ended

Sep. 24, 2016

Segment Reporting [Abstract]

Schedule of Revenue and Other Financial Information by Business Segment

The revised reportable segments are as follows:



Research Models and Services	Discovery and Safety Assessment	Manufacturing Support
Research Models	Discovery Services	Microbial Solutions
Research Model Services	Safety Assessment	Avian
		Biologics
		Contract Manufacturing

The following table presents revenue and other financial information by reportable segment:



	Three Months Ended				Nine Months Ended
	September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
RMS
Revenue	$	120,928	$	117,894	$	369,325	$	356,570
Operating income	31,224		31,427		103,055		93,581
Depreciation and amortization	5,245		5,279		15,613		16,590
Capital expenditures	2,532		3,022		5,966		12,111
DSA
Revenue	$	215,817	$	158,272	$	594,859	$	451,659
Operating income	31,303		33,191		94,514		84,856
Depreciation and amortization	20,671		11,509		51,228		35,060
Capital expenditures	4,509		4,277		13,860		13,756
Manufacturing
Revenue	$	88,975	$	73,299	$	250,459	$	201,223
Operating income	26,711		18,491		73,447		55,872
Depreciation and amortization	6,181		5,179		18,682		12,156
Capital expenditures	1,862		2,139		8,247		5,475

Reconciliation of Segment Operating Income to Consolidated Operating Income



	Operating Income						Depreciation and Amortization				Capital Expenditures
	September 24, 2016			September 26, 2015			September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
Total reportable segments	$	89,238		$	83,109		$	32,097	$	21,967	$	8,903	$	9,438
Unallocated corporate	(30,443		)	(27,669		)	2,011		1,847		665		1,014
Total consolidated	$	58,795		$	55,440		$	34,108	$	23,814	$	9,568	$	10,452



	Operating Income						Depreciation and Amortization				Capital Expenditures
	September 24, 2016			September 26, 2015			September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
Total reportable segments	$	271,016		$	234,309		$	85,523	$	63,806	$	28,073	$	31,342
Unallocated corporate	(102,688		)	(80,129		)	5,593		5,524		1,536		3,666
Total consolidated	$	168,328		$	154,180		$	91,116	$	69,330	$	29,609	$	35,008

Schedule of Net Sales for Each Significant Product or Service Offering

Revenue for each significant product or service offering is as follows:



	Three Months Ended				Nine Months Ended
	September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
RMS	$	120,928	$	117,894	$	369,325	$	356,570
DSA	215,817		158,272		594,859		451,659
Manufacturing	88,975		73,299		250,459		201,223
Total revenue	$	425,720	$	349,465	$	1,214,643	$	1,009,452

Summary of Unallocated Corporate Overhead

A summary of unallocated corporate expense consists of the following:



	Three Months Ended				Nine Months Ended
	September 24, 2016		September 26, 2015		September 24, 2016		September 26, 2015
	(in thousands)
Stock-based compensation	$	6,739	$	6,802	$	20,593	$	19,501
Compensation, benefits, and other employee-related expenses	9,048		6,821		29,327		24,751
External consulting and other service expenses	4,545		4,280		16,377		11,051
Information Technology	2,903		2,618		8,399		6,167
Depreciation	2,011		1,847		5,593		5,524
Acquisition and integration	2,033		3,478		13,056		7,072
Other general unallocated corporate	3,164		1,823		9,343		6,063
Total unallocated corporate expense	$	30,443	$	27,669	$	102,688	$	80,129

Basis of Presentation (Details) $ in Thousands	3 Months Ended		9 Months Ended
Basis of Presentation (Details) $ in Thousands	Sep. 24, 2016 USD ($)	Sep. 26, 2015 USD ($)	Sep. 24, 2016 USD ($) segments	Sep. 26, 2015 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments \| segments			3
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues	$ 425,720	$ 349,465	$ 1,214,643	$ 1,009,452
Operating income	58,795	55,440	168,328	154,180
Operating segments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Operating income	89,238	83,109	271,016	234,309
RMS \| Operating segments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues	120,928	117,894	369,325	356,570
Operating income	31,224	31,427	103,055	93,581
RMS \| Operating segments \| Reclassified Between Segments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues				(1,900)
Operating income				(200)
Manufacturing \| Operating segments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues	88,975	73,299	250,459	201,223
Operating income	$ 26,711	$ 18,491	$ 73,447	55,872
Manufacturing \| Operating segments \| Reclassified Between Segments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues				1,900
Operating income				$ 200

Business Acquisitions- Agilux Additional Information (Details) - Agilux Laboratories - USD ($) $ in Millions		3 Months Ended	9 Months Ended
	Sep. 28, 2016	Sep. 24, 2016	Sep. 24, 2016
Business Acquisition [Line Items]
Integration related costs and transaction costs		$ 1.1	$ 1.1
Subsequent Event
Business Acquisition [Line Items]
Purchase price	$ 64.0

Business Acquisitions- Blue Stream Additional Information (Details) - Blue Stream Laboratories $ in Thousands	Jun. 27, 2016 USD ($)
Business Acquisition [Line Items]
Purchase price	$ 11,700
Maximum contingent consideration	3,000
Total purchase price allocation	$ 11,704

Business Acquisitions- Blue Stream Purchase Price Allocation (Details) - USD ($) $ in Thousands	Sep. 24, 2016	Jun. 27, 2016	Dec. 26, 2015
Business Acquisition [Line Items]
Goodwill	$ 763,576		$ 438,829
Blue Stream Laboratories
Business Acquisition [Line Items]
Trade receivables, contractual amount		$ 1,104
Trade receivables		1,104
Other current assets (excluding cash)		15
Property, plant and equipment		912
Other long-term assets		187
Definite-lived intangible assets		1,230
Goodwill		10,433
Other current liabilities		(1,133)
Long-term liabilities		(1,044)
Total purchase price allocation		$ 11,704

Business Acquisitions- Blue Stream Definite Lived Intangible Assets (Details) - Blue Stream Laboratories $ in Thousands	Jun. 27, 2016 USD ($)
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 1,230
Weighted Average Amortization Life	7 years
Client relationships
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 650
Weighted Average Amortization Life	10 years
Other intangible assets
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 580
Weighted Average Amortization Life	5 years

Business Acquisitions- WIL Research Additional Information (Details) - WIL Research - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Apr. 04, 2016	Sep. 24, 2016	Sep. 24, 2016	Sep. 26, 2015
Business Acquisition [Line Items]
Purchase price	$ 604,800
Assumed liabilities	400
Total purchase price allocation	577,391
Cash acquired	27,400
Goodwill, expected tax deductible amount	$ 19,000
Integration related costs and transaction costs		$ 1,300	$ 13,700
Revenue		57,400	112,600
Operating income (loss)		$ 3,600	4,600
Amortization of intangible assets and depreciation of fixed assets			1,400	$ 5,800
Reversal of interest expense on borrowings			$ 2,700	8,200
Transaction costs				$ 9,800

Business Acquisitions- WIL Research Purchase Price Allocation (Details) - USD ($) $ in Thousands	Sep. 24, 2016	Apr. 04, 2016	Dec. 26, 2015
Business Acquisition [Line Items]
Goodwill	$ 763,576		$ 438,829
WIL Research
Business Acquisition [Line Items]
Trade receivables, contractual amount		$ 48,625
Trade receivables		48,157
Inventories		2,296
Other current assets (excluding cash)		4,021
Property, plant and equipment		129,066
Other long-term assets		1,060
Definite-lived intangible assets		165,400
Goodwill		330,229
Deferred revenue		(39,103)
Other current liabilities		(27,386)
Long-term liabilities		(36,349)
Total purchase price allocation		$ 577,391

Business Acquisitions- WIL Research Definite Lived Intangible Assets (Details) - WIL Research $ in Thousands	Apr. 04, 2016 USD ($)
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 165,400
Weighted Average Amortization Life	13 years
Client relationships
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 138,000
Weighted Average Amortization Life	15 years
Developed technology
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 20,700
Weighted Average Amortization Life	3 years
Backlog
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 6,700
Weighted Average Amortization Life	1 year

Business Acquisitions- WIL Research Pro Forma Financial Information (Details) - WIL Research - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Business Acquisition [Line Items]
Revenue	$ 425,720	$ 402,744	$ 1,275,175	$ 1,166,466
Net income attributable to common shareholders	$ 39,530	$ 40,931	$ 129,050	$ 116,863
Earnings per common share
Basic (in dollars per share)	$ 0.84	$ 0.88	$ 2.75	$ 2.51
Diluted (in dollars per share)	$ 0.82	$ 0.87	$ 2.70	$ 2.46

Business Acquisitions- Oncotest Additional Information (Details) - Oncotest $ in Thousands, € in Millions		3 Months Ended	9 Months Ended
	Nov. 18, 2015 USD ($)	Sep. 26, 2015 USD ($)	Sep. 26, 2015 USD ($)	Sep. 24, 2016 EUR (€)	Sep. 24, 2016 USD ($)
Business Acquisition [Line Items]
Integration related costs and transaction costs		$ 900	$ 900
Purchase price	$ 36,000
Contingent consideration	300
Maximum contingent consideration				€ 2.0	$ 2,200
Total purchase price allocation	35,431
Cash acquired	$ 600

Business Acquisitions- Oncotest Purchase Price Allocation (Details) - USD ($) $ in Thousands	Sep. 24, 2016	Dec. 26, 2015	Nov. 18, 2015
Business Acquisition [Line Items]
Goodwill	$ 763,576	$ 438,829
Oncotest
Business Acquisition [Line Items]
Trade receivables, contractual amount			$ 3,546
Trade receivables			3,520
Inventories			129
Other current assets (excluding cash)			706
Property, plant and equipment			2,528
Definite-lived intangible assets			13,330
Goodwill			22,894
Other long-term assets			250
Current liabilities			(3,456)
Long-term liabilities			(4,470)
Total purchase price allocation			$ 35,431

Business Acquisitions- Oncotest Definite Lived Intangible Assets (Details) - Oncotest $ in Thousands	Nov. 18, 2015 USD ($)
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 13,330
Weighted Average Amortization Life	19 years
Client relationships
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 7,146
Weighted Average Amortization Life	19 years
Developed technology
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 5,960
Weighted Average Amortization Life	19 years
Other intangible assets
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 224
Weighted Average Amortization Life	3 years

Business Acquisitions - Celsis, Additional Information (Details) - Celsis - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Jul. 24, 2015	Sep. 26, 2015	Sep. 26, 2015
Business Acquisition [Line Items]
Purchase price	$ 214,500
Assumed liabilities	10,300
Total purchase price allocation	212,236
Cash acquired	$ 2,300
Integration related costs and transaction costs		$ 3,900	$ 7,400
Revenue		4,900	4,900
Operating income (loss)		$ (3,100)	(3,100)
Depreciation, amortization, and Write-down of Inventory			$ 2,400

Business Acquisitions - Celsis Purchase Price Allocation (Details) - USD ($) $ in Thousands	Sep. 24, 2016	Dec. 26, 2015	Jul. 24, 2015
Business Acquisition [Line Items]
Goodwill	$ 763,576	$ 438,829
Celsis
Business Acquisition [Line Items]
Trade receivables, contractual amount			$ 5,410
Trade receivables			5,288
Inventories			10,103
Other current assets (excluding cash)			13,269
Property, plant and equipment			4,639
Definite-lived intangible assets			118,140
Goodwill			105,550
Other long-term assets			537
Current debt			(9,766)
Other current liabilities			(7,136)
Long term liabilities			(28,388)
Total purchase price allocation			$ 212,236

Business Acquisitions - Celsis Definite-Lived Intangible Assets (Details) - Celsis $ in Thousands	Jul. 24, 2015 USD ($)
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 118,140
Weighted Average Amortization Life	15 years
Client relationships
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 71,000
Weighted Average Amortization Life	16 years
Developed technology
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 39,140
Weighted Average Amortization Life	14 years
Trademark and trade names
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 5,200
Weighted Average Amortization Life	14 years
Non-compete
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 2,800
Weighted Average Amortization Life	5 years

Business Acquisitions Business Acquisitions- Celsis Pro Forma Financial Information (Details) - Celsis - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 26, 2015	Sep. 26, 2015
Business Acquisition [Line Items]
Revenue	$ 350,819	$ 1,026,643
Net income attributable to common shareholders	$ 40,826	$ 125,863
Earnings (loss) per common share
Basic (in dollars per share)	$ 0.88	$ 2.70
Diluted (in dollars per share)	$ 0.86	$ 2.65

Business Acquisitions - Sunrise, Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended		12 Months Ended
	May 05, 2015	Sep. 24, 2016	Sep. 24, 2016	Sep. 26, 2015	Dec. 26, 2015
Business Acquisition [Line Items]
Gain on bargain purchase			$ (16)	$ 9,933
Sunrise
Business Acquisition [Line Items]
Purchase price	$ 9,558
Gain on bargain purchase	9,821				$ 9,900
Cash acquired	$ 100
Integration related costs and transaction costs		$ 100	$ 700
Sunrise \| Client relationships
Business Acquisition [Line Items]
Useful life of intangible assets acquired			15 years

Business Acquisitions - Sunrise Purchase Price Allocation (Details) - USD ($) $ in Thousands		9 Months Ended		12 Months Ended
	May 05, 2015	Sep. 24, 2016	Sep. 26, 2015	Dec. 26, 2015
Business Acquisition [Line Items]
Bargain purchase gain		$ 16	$ (9,933)
Sunrise
Business Acquisition [Line Items]
Trade receivables, contractual amount	$ 995
Trade receivables	965
Inventories	1,518
Other current assets (excluding cash)	973
Property, plant and equipment	13,698
Definite-lived intangible assets	3,400
Current liabilities	(925)
Long-term liabilities	(250)
Fair value of net assets acquired	19,379
Bargain purchase gain	(9,821)			$ (9,900)
Total purchase price allocation	$ 9,558

Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 24, 2016	Dec. 26, 2015
Composition of trade receivables
Client receivables	$ 278,041	$ 230,010
Unbilled revenue	84,754	45,996
Total	362,795	276,006
Less: Allowance for doubtful accounts	(3,061)	(5,938)
Trade receivables, net	359,734	270,068
Composition of inventories
Raw materials and supplies	18,445	15,998
Work in process	14,119	12,101
Finished products	66,810	65,636
Inventories	99,374	93,735
Composition of other current assets
Investments	7,734	20,516
Prepaid income taxes	44,467	26,350
Restricted cash	572	271
Other	148	149
Other current assets	52,921	47,286
Composition of other assets
Life insurance policies	28,837	27,554
Venture capital investments	45,653	32,730
Restricted cash	1,825	1,745
Other	10,014	9,614
Other assets	86,329	71,643
Composition of other current liabilities
Accrued income taxes	24,138	12,168
Accrued interest and other	993	376
Other current liabilities	25,131	12,544
Composition of other long-term liabilities
Long-term pension liability	32,639	34,604
Accrued executive supplemental life insurance retirement plan and deferred compensation plan	31,244	30,188
Other	32,888	24,270
Other long-term liabilities	$ 96,771	$ 89,062

Venture Capital Investments and Marketable Securities - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 03, 2016	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015	Dec. 26, 2015
Schedule of Equity Method Investments [Line Items]
Committed contribution		$ 80,600,000		$ 80,600,000
Committed contributions funded		35,300,000		35,300,000
Dividends received		2,303,000	$ 5,300,000	2,300,000	$ 7,300,000
Gain (loss) from venture capital investments		400,000	$ 3,200,000
Marketable securities		0		0		$ 4,509,000
Proceeds from sale of available-for-sale securities		$ 4,600,000		$ 4,600,000	$ 0
Minimum
Schedule of Equity Method Investments [Line Items]
Ownership percentage		2.70%		2.70%
Maximum
Schedule of Equity Method Investments [Line Items]
Ownership percentage		12.00%		12.00%
Subsequent Event
Schedule of Equity Method Investments [Line Items]
Increase in committed contribution	$ 4,300,000

Venture Capital Investments and Marketable Securities - Summary of Marketable Securities (Details) - USD ($)	Sep. 24, 2016	Dec. 26, 2015
Schedule of Available-for-sale Securities [Line Items]
Cost		$ 4,650,000
Gross Unrealized Gains		0
Gross Unrealized Losses		(141,000)
Fair Value	$ 0	4,509,000
Mutual fund
Schedule of Available-for-sale Securities [Line Items]
Cost		4,650,000
Gross Unrealized Gains		0
Gross Unrealized Losses		(141,000)
Fair Value		$ 4,509,000

Fair Value - Fair Value of Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 24, 2016	Dec. 26, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 14	$ 190
Other current assets:
Mutual funds		4,509
Foreign currency forward contracts		15
Other assets:
Life insurance policies	21,521	20,364
Total assets measured at fair value	21,535	25,078
Other current liabilities:
Contingent consideration	4,126	1,172
Other long-term liabilities:
Contingent consideration		198
Redeemable noncontrolling interest		28,008
Total liabilities and redeemable noncontrolling interest measured at fair value	4,126	29,378
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Other current assets:
Mutual funds		4,509
Foreign currency forward contracts		0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	4,509
Other current liabilities:
Contingent consideration	0	0
Other long-term liabilities:
Contingent consideration		0
Redeemable noncontrolling interest		0
Total liabilities and redeemable noncontrolling interest measured at fair value	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	14	190
Other current assets:
Mutual funds		0
Foreign currency forward contracts		15
Other assets:
Life insurance policies	21,521	20,364
Total assets measured at fair value	21,535	20,569
Other current liabilities:
Contingent consideration	0	0
Other long-term liabilities:
Contingent consideration		0
Redeemable noncontrolling interest		0
Total liabilities and redeemable noncontrolling interest measured at fair value	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Other current assets:
Mutual funds		0
Foreign currency forward contracts		0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Other current liabilities:
Contingent consideration	4,126	1,172
Other long-term liabilities:
Contingent consideration		198
Redeemable noncontrolling interest		28,008
Total liabilities and redeemable noncontrolling interest measured at fair value	$ 4,126	$ 29,378

Fair Value - Contingent Consideration (Details) - Contingent Consideration - USD ($) $ in Thousands	9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 1,370	$ 2,828
Additions	3,600	675
Payments	(874)	(600)
Total gains or losses (realized/unrealized):
Reversal of previously recorded contingent liability and change in fair value	30	(1,623)
September 24, 2016	$ 4,126	$ 1,280

Fair Value - Redeemable Noncontrolling Interest (Details) - USD ($) $ in Thousands		9 Months Ended
	Jul. 07, 2016	Sep. 24, 2016	Dec. 26, 2015	Jan. 31, 2013
Total gains or losses (realized/unrealized):
Ending balance		$ 15,040	$ 28,008
Vital River
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Percentage of voting interests acquired	12.00%	87.00%		75.00%
Remaining ownership percentage available		13.00%		25.00%
Purchase of additional equity interest	$ 10,800
Gain in additional paid-in-capital equal to the excess fair value of equity interest over the purchase price	1,600
Charge in other other income (expense), net equal to the excess fair value of the hybrid instrument over the fair value of the underlying equity interest	$ 1,500
Vital River \| Level 3 \| Redeemable Noncontrolling Interest
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		$ 28,008
Purchase of 12% equity interest		(12,360)
Total gains or losses (realized/unrealized):
Foreign currency translation		(875)
Change in fair value, included in additional paid-in capital		(1,690)
Vital River \| Level 3 \| Redeemable Noncontrolling Interest \| Net income attributable to noncontrolling interest
Total gains or losses (realized/unrealized):
Net income attributable to noncontrolling interest		462
Vital River \| Level 3 \| Redeemable Noncontrolling Interest \| Other income (expense)
Total gains or losses (realized/unrealized):
Net income attributable to noncontrolling interest		$ 1,495

Goodwill and Intangible Assets - Gross Carrying Amount and Accumulated Amortization of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 24, 2016 USD ($)
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	$ 438,829
Adjustments to Goodwill, Acquisitions	340,832
Adjustments to Goodwill, Transfers	0
Adjustments to Goodwill, Foreign Exchange	(16,085)
Gross carrying amount, balance at the end of the period	763,576
RMS
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	58,167
Adjustments to Goodwill, Acquisitions	0
Adjustments to Goodwill, Transfers	(342)
Adjustments to Goodwill, Foreign Exchange	(479)
Gross carrying amount, balance at the end of the period	57,346
DSA
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	247,050
Adjustments to Goodwill, Acquisitions	293,973
Adjustments to Goodwill, Transfers	0
Adjustments to Goodwill, Foreign Exchange	(7,914)
Gross carrying amount, balance at the end of the period	533,109
Manufacturing
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	133,612
Adjustments to Goodwill, Acquisitions	46,859
Adjustments to Goodwill, Transfers	342
Adjustments to Goodwill, Foreign Exchange	(7,692)
Gross carrying amount, balance at the end of the period	$ 173,121

Goodwill and Intangible Assets - Schedule of Other Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Sep. 24, 2016	Dec. 26, 2015
Other intangible assets
Gross		$ 621,828	$ 533,661
Accumulated Amortization		(225,376)	(252,857)
Net		396,452	280,804
Impairment charge	$ 1,900
Backlog
Other intangible assets
Gross		8,645	50,568
Accumulated Amortization		(4,979)	(50,554)
Net		3,666	14
Technology
Other intangible assets
Gross		74,304	60,350
Accumulated Amortization		(11,910)	(5,911)
Net		62,394	54,439
Trademarks and trade names
Other intangible assets
Gross		8,439	11,495
Accumulated Amortization		(4,029)	(5,944)
Net		4,410	5,551
Other
Other intangible assets
Gross		12,390	14,711
Accumulated Amortization		(5,159)	(7,285)
Net		7,231	7,426
Other intangible assets
Other intangible assets
Gross		103,778	137,124
Accumulated Amortization		(26,077)	(69,694)
Net		77,701	67,430
Client relationships
Other intangible assets
Gross		518,050	396,537
Accumulated Amortization		(199,299)	(183,163)
Net		$ 318,751	$ 213,374

Long-Term Debt and Capital Lease Obligations - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	Sep. 24, 2016	Dec. 26, 2015
Debt Instrument [Line Items]
Total debt	$ 1,238,401	$ 836,234
Less: current portion of long-term debt	(24,572)	(15,193)
Long-term debt	1,213,829	821,041
Debt discount and debt issuance costs	(8,139)	(6,805)
Long-term debt, net	1,205,690	814,236
Term loans
Debt Instrument [Line Items]
Total debt	641,875	390,000
Revolving credit facility
Debt Instrument [Line Items]
Total debt	596,329	446,041
Other long-term debt
Debt Instrument [Line Items]
Total debt	$ 197	$ 193

Long-Term Debt and Capital Lease Obligations - Additional Information (Details)		1 Months Ended
	Mar. 30, 2016 USD ($) payment	Apr. 30, 2015 USD ($)	Sep. 24, 2016 USD ($)	Mar. 29, 2016 USD ($)	Dec. 26, 2015 USD ($)	Mar. 31, 2015 USD ($)
Debt Instrument [Line Items]
Weighted average interest rate			1.95%		1.33%
Credit facility	$ 1,650,000,000.00	$ 1,300,000,000.0		$ 1,300,000,000.0		$ 970,000,000
Capitalized debt issuance costs	3,300,000
Expensed debt issuance costs	1,400,000
Maximum borrowing capacity, term loan and line of credit facility, potential increase available	$ 500,000,000
Credit facility
Debt Instrument [Line Items]
Minimum EBITDA less capital expenditures to consolidated cash interest expense ratio	3.50
Maximum consolidated indebtedness to consolidated EBITDA	4.25
Maximum consolidated indebtedness to consolidated EBITDA	3.50
Other Capital Lease Obligations
Debt Instrument [Line Items]
Other capital lease obligations			$ 28,900,000		$ 33,600,000
Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding			$ 5,100,000		$ 4,900,000
Federal Funds Rate
Debt Instrument [Line Items]
Interest rate	0.50%	0.50%
LIBOR
Debt Instrument [Line Items]
Interest rate	1.00%	1.00%
Term Loan Facility
Debt Instrument [Line Items]
Credit facility	$ 650,000,000.0	$ 400,000,000.0
Number of quarterly installment payments \| payment	19
Multi-currency Revolving Facility
Debt Instrument [Line Items]
Credit facility	$ 1,000,000,000.0	$ 900,000,000.0

Equity - Earnings Per Share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Numerator:
Income from continuing operations, net of income taxes	$ 37,691	$ 37,901	$ 110,811	$ 118,774
Less: Income (loss) from discontinued operations, net of income taxes	342	(34)	328	(48)
Less: Net income attributable to noncontrolling interests	298	488	1,054	1,297
Net income attributable to common shareholders	$ 37,735	$ 37,379	$ 110,085	$ 117,429
Denominator:
Weighted-average shares outstanding—Basic (in shares)	47,160	46,290	46,954	46,572
Effect of dilutive securities:
Stock options, restricted stock units, performance share units and restricted stock (in shares)	874	955	884	1,012
Weighted-average shares outstanding—Diluted (in shares)	48,034	47,245	47,838	47,584

Equity - Earnings Per Share, Additional Information (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	0.6	0.5	0.9	0.5
Restricted Stock, Restricted Stock Units, and Performance Share Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)			1.1	1.1

Equity - Treasury Shares (Details) - USD ($) $ in Thousands, shares in Millions	9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015
Treasury Shares
Purchase of treasury stock	$ 12,226	$ 117,431
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments (in shares)	0.2	0.1
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments	$ 12,200	$ 8,700
Authorized Share Repurchase Program
Treasury Shares
Stock repurchased during period (in shares)		1.5
Purchase of treasury stock		$ 108,800
Remaining authorized repurchase amount	$ 69,700

Equity - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Other comprehensive loss before reclassifications			$ (31,735)
Amounts reclassified from accumulated other comprehensive income (loss)			1,961
Net current period other comprehensive income			(29,774)
Income tax expense	$ 140	$ 220	424	$ 700
Foreign Currency Translation Adjustment and Other
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
December 26, 2015			(82,977)
Other comprehensive loss before reclassifications			(31,735)
Amounts reclassified from accumulated other comprehensive income (loss)			0
Net current period other comprehensive income			(31,735)
Income tax expense			0
September 24, 2016	(114,712)		(114,712)
Pension and Other Post-Retirement Benefit Plans
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
December 26, 2015			(52,571)
Other comprehensive loss before reclassifications			0
Amounts reclassified from accumulated other comprehensive income (loss)			1,961
Net current period other comprehensive income			1,961
Income tax expense	100	$ 200	424	$ 700
September 24, 2016	(51,034)		(51,034)
Total
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
December 26, 2015			(135,548)
September 24, 2016	$ (165,746)		$ (165,746)

Income Taxes (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	May 05, 2015	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015	Dec. 26, 2015
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Effective tax rate (as a percentage)		29.20%	28.70%	30.40%	18.30%
Tax benefit resulting from enacted U.K. tax law change		$ 1,400
Prior year reduction in unrecognized tax benefits and related interest				$ 10,400
Gain on bargain purchase				(16)	$ 9,933
Increase (decrease) in unrecognized tax benefits		200
Unrecognized tax benefits		25,500		25,500
Unrecognized tax benefits that would impact effective tax rate favorably, if recognized		22,200		22,200
Accrued interest on unrecognized tax benefits		1,600		1,600
Accrued penalties on unrecognized tax benefits		200		200
Possible decrease of unrecognized tax benefits		3,500		3,500
Income tax expense related to items of other comprehensive income		140	$ 220	424	700
Pension and Other Post-Retirement Benefit Plans
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Income tax expense related to items of other comprehensive income		$ 100	$ 200	$ 424	$ 700
Sunrise
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Gain on bargain purchase	$ 9,821					$ 9,900

Pension and Other Post-Retirement Benefit Plans (Details) - Pension Plans - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Employee benefits
Service cost	$ 655	$ 1,149	$ 1,848	$ 3,448
Interest cost	2,773	3,335	9,357	10,006
Expected return on plan assets	(3,038)	(4,383)	(11,028)	(13,147)
Amortization of prior service benefit	(142)	(150)	(430)	(451)
Amortization of net loss	503	845	1,594	2,636
Settlements	788	0	788	0
Net periodic cost	$ 1,539	$ 796	$ 2,129	$ 2,492

Stock-Based Compensation - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Stock-based compensation expense
Stock-based compensation, before income taxes	$ 10,600	$ 10,476	$ 32,647	$ 30,349
Provision for income taxes	(3,785)	(3,733)	(11,653)	(10,737)
Stock-based compensation, net of income taxes	6,815	6,743	20,994	19,612
Cost of revenue
Stock-based compensation expense
Stock-based compensation, before income taxes	1,608	1,670	4,957	4,959
Selling, general and administrative
Stock-based compensation expense
Stock-based compensation, before income taxes	$ 8,992	$ 8,806	$ 27,690	$ 25,390

Stock-Based Compensation - Summary of Stock-Based Compensation Grants (Details) shares in Millions	9 Months Ended
	Sep. 24, 2016 $ / shares shares
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)	0.6
Stock options weighted average grant date fair value (in dollars per share) \| $ / shares	$ 15.12
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.2
Weighted-average grant date fair value (in dollars per share) \| $ / shares	$ 75.13
Performance Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.2
Weighted-average grant date fair value (in dollars per share) \| $ / shares	$ 79.81
Maximum shares to be awarded under plan (in shares)	0.4

Foreign Currency Contracts - Notional Amount and Fair Value (Details) - Foreign Currency Forward Contract $ in Thousands	Dec. 26, 2015 USD ($)
Derivative [Line Items]
Other current assets, notional amount	$ 88,483
Other Current Assets
Derivative [Line Items]
Other current assets, fair value	$ 15

Foreign Currency Contracts - Effect on Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Other income (expense), net \| Foreign Currency Forward Contract
Derivatives, Fair Value [Line Items]
Gain (Loss) Recognized	$ 0	$ (3,194)	$ 3,373	$ (3,194)

Commitments and Contingencies (Details) $ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
Commitments and Contingencies (Details) $ in Millions	Jul. 31, 2015 patent	Sep. 24, 2016 USD ($)	Sep. 24, 2016 USD ($)	Jun. 25, 2016 USD ($)
Loss Contingencies [Line Items]
Increase in lease obligations			$ 22.5
Government billing
Loss Contingencies [Line Items]
Reserve for estimated possible loss		$ 1.8	$ 1.8	$ 1.5
Increase in reserve for estimated possible loss		$ 0.3
Pending Litigation \| Idexx
Loss Contingencies [Line Items]
Number of patents infringed upon \| patent	3

Segment Information - Revenue and Other Financial Information by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Segment Reporting Information [Line Items]
Revenue	$ 425,720	$ 349,465	$ 1,214,643	$ 1,009,452
Operating income	58,795	55,440	168,328	154,180
Depreciation and amortization	34,108	23,814	91,116	69,330
Capital expenditures	9,568	10,452	29,609	35,008
Operating segments
Segment Reporting Information [Line Items]
Operating income	89,238	83,109	271,016	234,309
Depreciation and amortization	32,097	21,967	85,523	63,806
Capital expenditures	8,903	9,438	28,073	31,342
RMS \| Operating segments
Segment Reporting Information [Line Items]
Revenue	120,928	117,894	369,325	356,570
Operating income	31,224	31,427	103,055	93,581
Depreciation and amortization	5,245	5,279	15,613	16,590
Capital expenditures	2,532	3,022	5,966	12,111
DSA \| Operating segments
Segment Reporting Information [Line Items]
Revenue	215,817	158,272	594,859	451,659
Operating income	31,303	33,191	94,514	84,856
Depreciation and amortization	20,671	11,509	51,228	35,060
Capital expenditures	4,509	4,277	13,860	13,756
Manufacturing \| Operating segments
Segment Reporting Information [Line Items]
Revenue	88,975	73,299	250,459	201,223
Operating income	26,711	18,491	73,447	55,872
Depreciation and amortization	6,181	5,179	18,682	12,156
Capital expenditures	$ 1,862	$ 2,139	$ 8,247	$ 5,475

Segment Information - Reconciliation of Segment Operating Income, Depreciation and Amortization, and Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Segment Reporting Information [Line Items]
Operating income	$ 58,795	$ 55,440	$ 168,328	$ 154,180
Depreciation and amortization	34,108	23,814	91,116	69,330
Capital expenditures	9,568	10,452	29,609	35,008
Total reportable segments
Segment Reporting Information [Line Items]
Operating income	89,238	83,109	271,016	234,309
Depreciation and amortization	32,097	21,967	85,523	63,806
Capital expenditures	8,903	9,438	28,073	31,342
Unallocated corporate
Segment Reporting Information [Line Items]
Operating income	(30,443)	(27,669)	(102,688)	(80,129)
Depreciation and amortization	2,011	1,847	5,593	5,524
Capital expenditures	$ 665	$ 1,014	$ 1,536	$ 3,666

Segment Information - Revenue Per Significant Product or Service (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Segment Reporting Information [Line Items]
Revenue	$ 425,720	$ 349,465	$ 1,214,643	$ 1,009,452
Operating segments \| RMS
Segment Reporting Information [Line Items]
Revenue	120,928	117,894	369,325	356,570
Operating segments \| DSA
Segment Reporting Information [Line Items]
Revenue	215,817	158,272	594,859	451,659
Operating segments \| Manufacturing
Segment Reporting Information [Line Items]
Revenue	$ 88,975	$ 73,299	$ 250,459	$ 201,223

Segment Information - Summary of Unallocated Corporate Overhead (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 24, 2016	Sep. 26, 2015	Sep. 24, 2016	Sep. 26, 2015
Segment Reporting Information [Line Items]
Stock-based compensation	$ 10,600	$ 10,476	$ 32,647	$ 30,349
Unallocated corporate
Segment Reporting Information [Line Items]
Stock-based compensation	6,739	6,802	20,593	19,501
Compensation, benefits, and other employee-related expenses	9,048	6,821	29,327	24,751
External consulting and other service expenses	4,545	4,280	16,377	11,051
Information Technology	2,903	2,618	8,399	6,167
Depreciation	2,011	1,847	5,593	5,524
Acquisition and integration	2,033	3,478	13,056	7,072
Other general unallocated corporate	3,164	1,823	9,343	6,063
Total unallocated corporate expense	$ 30,443	$ 27,669	$ 102,688	$ 80,129